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HEAT SHOCK PROTEIN 70 REGULATES TUMOR NECROSIS FACTOR-ΑLPHA AND 
MYOGENIN IN SKELETAL MUSCLE FOLLOWING CHEMICAL-INDUCED INJURY 
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Under the Guidance of Jeff S. Otis, Ph.D. 
 
ABSTRACT 
Skeletal muscle injury results in functional deficits that can take several weeks to fully recover. 
Ultimate recovery of function is dependent on the muscle’s ability to regenerate, a highly 
coordinated process that involves transient muscle inflammation and the replacement of 
damaged myofibers.  Instrumental in the inflammatory response, is the pro-inflammatory 
cytokine TNF-α.  Expression of TNF-α is thought to be regulated, in part, by the stress sensing 
70 kDa heat shock protein (Hsp70).  However, it remains unclear how Hsp70 alters TNF-α 
following injury, and if so, how these changes affect skeletal muscle repair.  Therefore, we up-
regulated Hsp70 expression using 17-allylamino-17-demethoxygeldanamycin (17-AAG) prior to 
and following BaCl2-induced injury, and assessed TNF-α and myogenin content.  Regenerating 
 fiber cross-sectional area (CSA) and in vivo isometric torque were also analyzed in the weeks 
following the injury.  Treatment of 17-AAG resulted in a ~5 fold increase in Hsp70 of the 
uninjured muscle, but did not affect any other biochemical, morphological or functional variables 
compared to controls.  In the days following the injury, TNF-α and myogenin were elevated and 
directly correlated.  At these earlier time points (≤7 days), treatment of 17-AAG increased TNF-
α above that of the injured controls and resulted in a sustained increase in myogenin.  However, 
no differences were observed in regenerating fiber CSA or in vivo torque production between the 
groups.  Together, these data suggest that Hsp70 induction increases TNF-α and myogenin 
content following BaCl2-induced injury, but does not appear to alter skeletal muscle 
regeneration or attenuate functional deficits in otherwise healthy young mice. 
 
INDEX WORDS:  Heat shock protein, Injury, Myogenin, Skeletal Muscle, TNF-α 
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1 SKELETAL MUSCLE INJURY AND RECOVERY 
 
Introduction 
Skeletal muscle is a remarkable tissue; it allows for force production to perform tasks required to 
sustain life, such as breathing and locomotion.  When injured, the ability of the skeletal muscle 
to perform these tasks is compromised.  Skeletal muscle injury often results in the physical 
disruption of muscle structures involved in the production or transmission of force (126).  
Furthermore, chronic injury or genetic diseases can blunt its regenerative capacity and lead to 
muscle wasting and further dysfunction.  Therefore, it is vital to study the mechanisms of 
strength loss associated with injury and degeneration, as well as the regenerative processes that 
follow.   
 In response to injury (i.e., contraction- or trauma-induced), a well-orchestrated and 
coordinated series of cellular and molecular events are observed (54, 60).  The injury results in 
necrosis of damaged tissue, which induces a rapid and sequential inflammatory response.  
Morphological analysis reveals interstitial edema with invading leukocytes (e.g., neutrophils, 
monocytes, macrophages) (21).  These immune cells phagocytize necrotic tissue and release 
several cytokines.  Initially, pro-inflammatory cytokines such as tumor necrosis factor alpha 
(TNFα), interleukin-1 beta (IL-1β), and interleukin-6 (IL-6) are released that increase satellite 
cell (SC) activation and muscle progenitor cell (MPC) proliferation.  When proliferation is 
blocked through irradiation, the muscle’s ability to functionally return to its pre-injured state is 
significantly delayed (101).   MPC differentiate and fuse to form small basophilic centro-
nucleated myotubes (the hallmark of skeletal muscle regeneration).  Fusion of myoblasts and 
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further growth of the newly regenerated centro-nucleated myofibers result in the restoration of 
the cellular architecture within the following weeks of injury (Figure 1) (48, 106). 
 
 
Figure 1. Depiction of regeneration mediated through SC activity. 
 
 In the event that any of these steps are blunted or inhibited, the ultimate recovery of the 
muscle will be prolonged.  The transcription factor, nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB), often referred to as the central mediator of the human immune 
response (97) is a key regulator in skeletal muscle degeneration and regeneration.  On one hand, 
NF-κB orchestrates the inflammatory response by releasing the aforementioned pro-
inflammatory cytokines that recruit leukocytes, which release reactive oxygen species (ROS) and 
proteases that assist in phagocytosis (21).  In parallel, these cytokines also activate SCs and 
cause MPC proliferation (96).  However, ROS (8) and TNFα (34, 67) are also known to inhibit 
MPC differentiation, thereafter blunting and delaying regeneration.  Furthermore, NF-κB-derived 
ROS and pro-inflammatory cytokines can activate NF-κB (97), thus creating a positive feedback 
loop that prolongs NF-κB-derived signaling. 
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 Many proteins are involved in the regulation of NF-κB (97).  For example, heat shock 
protein 70 (Hsp70) is generally known for its role as a molecular chaperone and stress sensor that 
refolds denatured proteins (50, 70), but it is also an inhibitor of NF-κB (35, 82, 95, 105).  Several 
recent studies have demonstrated that up-regulation of Hsp70 reduces histological damage (63, 
64, 80, 84) and attenuates strength deficits following injury (63, 80).  Though the precise 
mechanisms for this enhancement are unknown, increasing evidence suggest NF-κB is a central 
player (35, 82, 95, 105).  Therefore, this review will outline skeletal muscle injury and recovery, 
the roles of Hsp70 in muscular regeneration and how regeneration is orchestrated between Hsp70 
and NF-κB. 
 
Models of skeletal muscle injury 
Numerous injury models have been used to examine skeletal muscle regenerative mechanisms.  
Injury models are broadly characterized into two categories: contraction- or trauma-induced.  
Contraction-induced injury is the result of strenuous exercise or eccentric contractions.  In 
comparison to concentric or isometric muscle actions, eccentric contractions are unique in the 
fact that they generate higher forces (10, 29) and for a given muscle force, require the 
requirement of fewer muscle fibers (65, 87).  Thus, these high forces distributed across a 
relatively small population of fibers place a great deal of stress and strain on the muscle, making 
them susceptible to damage.  Contraction-induced injury is more common than traumatic injuries 
(137).  
 In contrast, trauma-induced models occur independently of muscle contraction and 
include exposure to toxins, extreme temperatures, crushing, laceration, blunt impact or ischemia.  
The most reproducible traumatic injuries utilize chemical agents such as snake venoms (e.g., 
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notexin, cardiotoxin) or barium chloride (BaCl2) (28, 30, 96).  A notexin is a myotoxic 
phospholipase A2 derived from the venom of the Australian tiger snake, while a cardiotoxin is a 
set of small proteins found in cobra venom that causes skeletal muscle contracture and interferes 
with neuromuscular transmission.  Alternatively, BaCl2 induces necrosis by causing muscle 
depolarization by stimulating exocytosis and blocking the efflux of calcium (Ca2+).   
 Regardless, the healing phases for an injured muscle including degeneration, 
inflammation, regeneration and remodeling are similar between injury types (54, 60), even 
though the initial mechanism of damage may differ.  Furthermore, the current therapeutic 
approaches for treating muscle injuries are dependent not on the type of injury but rather the 
clinical severity (60).  In the event the muscle does not heal properly, it will lead to an 
incomplete functional recovery, a tendency for recurrent injuries and/or scar tissue formation 
(54). 
 
Characteristics of skeletal muscle injury 
Many different markers are used to characterize injury, including alterations to fiber 
morphology, changes in intracellular proteins levels and localization, loss of intracellular muscle 
proteins to the surrounding environment and reductions to muscle function (126).  By measuring 
changes in these markers it is possible to describe the magnitude and duration of the injury.  
Evidence of injury can be classified as direct, biochemical/histochemical or functional (126). 
 Direct evidence of muscle damage observed from muscle biopsies 
Using light microscopy, focal disruptions to the striated banding patterns and ultra-structural 
features are evident immediately after injury, and worsen between 30 hours and 3 days post 
contraction-induced injury (41).  Similarly, Z-line streaming is also observed at these later time 
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points using electron microscopy (41).  Z-line streaming is one of the principle ultra-structural 
abnormalities seen after eccentric exercise (39) and may represent a weak link in the contractile 
chain of the myofibril (40).  Other abnormalities include disrupted A band (41) and I band (77) 
filaments, transverse (T)-tubules and triads (116), sarcoplasmic reticulum (SR) (94), and 
extracellular matrix and capillaries (113), the presence of autophagic vacuoles (41) and central 
nuclei (44), swollen or missing mitochondria (41) and alterations to the cytoskeletal structure 
(39).  
 Biochemical and histochemical evidence of muscle damage 
Muscle damage is also evident using biochemical analyses of bodily fluids and histochemical 
analysis of tissue.  After injury it is common to assess blood levels or activity of circulating 
neutrophils and macrophages, cytokines and/or muscle proteins.  Some of more common muscle 
proteins analyzed after injury include: creatine kinase (CK), myoglobin, lactate dehydrogenase, 
aspartate aminotransferase and Beta-glucuronidase (126). 
 Functional evidence of muscle damage 
Functional evidence of muscle damage includes changes in range of motion and stiffness of 
muscle and joints, swelling, soreness, low frequency fatigue and strength loss and recovery.   
Following contraction-induced injury, voluntary range of motion (i.e., the distance and direction 
through which a joint can move) decreases, while circumference measurements increase due to 
swelling (93).  Pain typically develops 2 to 4 days after exercise and is abated at 5 to 7 days post-
injury (26).  This pain, first described by Hough (53), is referred to as delayed onset muscle 
soreness (DOMS).  DOMS is one of the hallmark manifestations of exercise-induced damage 
and is often assessed qualitatively in human studies as a marker of injury. 
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 Other markers of injury include low frequency fatigue, and strength loss and recovery.  
Low-frequency fatigue is characterized by a relative loss of force at low frequencies of 
stimulation that slowly recovers over the course of hours/days due to reductions in Ca2+ release 
(62).  The final marker of damage is loss and recovery of muscular strength.  Warren et al. (137) 
considers loss of strength to be one of the most valid and reliable indirect markers of exercise-
induced muscle damage.  Strength deficits following eccentric exercise outlast changes in 
metabolite levels and therefore are not associated with fatigue (38).  Strength loss and recovery is 
dependent on the mode, intensity and duration of the exercise.  For example, downhill running 
typically results in immediate reductions in strength ranging from 10 to 30% (9, 25) that often 
recovers in 1 week.  On the other hand, electrically stimulated maximal eccentric contractions in 
animal models can exceed strength deficits of 50% and take several weeks to fully recover (10, 
74, 101).   
 Traumatic muscle injuries including crush, contusion, laceration or freezing occur 
relatively infrequently but when they do occur, can have dramatic and prolonged effects on the 
muscle’s functional capacity.  For example, Warren et al. (139) reported freeze injury reduced 
maximal isometric strength ~70% while Rogers, Baumann and Otis (unpublished data) 
demonstrated strength deficits of 80% after BaCl2-induced injury. 
 
Strength deficits associated with skeletal muscle injury 
The contributors of strength loss will be dependent on the injury model.  Over the past 2 decades 
a great deal of effort has been directed into understanding the mechanisms of strength loss after 
contraction-induced injury and thus will be highlighted in detail in the following sections.  
 7 
 
Because the initial damaging events differ between contraction and trauma induced-injury 
models, trauma-induced injury will discussed after contraction-induced injury.  
 Damage to force generating structures after contraction-induced injury 
Based on the principle that muscle force production is directly related to a muscle’s functional 
area (i.e., physiological cross sectional area: CSA), immediate strength deficits were initially 
thought to be due solely to damage of force bearing proteins (3).  However, further research has 
suggested physical damage only accounts for a portion of the strength loss immediately and up to 
3 days post-injury (74, 134-136). 
 The first line of evidence to suggest that physical damage is not the sole cause of early 
strength deficits is the disconnect between histological damage and strength loss both temporally 
and quantitatively.  This disconnect was demonstrated by Warren et al. (134) who found that the 
performance of 15 eccentric contractions in vitro in mouse extensor digitorum longus (EDL) 
muscle resulted in specific force deficits of over 60%.  However, signs of damage per cross 
section were only visible in ~3% of the fibers immediately after the injury.  Further, Lowe et al. 
(74) reported for mouse muscles exhibiting strength loss of 50%, no more than 5% of the fibers 
in cross-section showed histopathology at any time in the first 2 weeks following injury.  In 
contrary, it is also possible to have robust muscle damage without a marked reduction in force 
production (52, 91, 92, 114).  Street and Ramsey (114) suggest the ability of the muscle to 
generate near maximal force despite being damaged may be attributed to lateral transmission of 
force propagated by the still-intact sarcolemma.  From these results, it is clear that a great deal of 
variability exists when comparing direct histological damage and strength loss, making it 
difficult to draw accurate conclusions. 
 The second line of evidence is achieved through direct activation of the myofilaments 
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through the application of maximally activating Ca2+ in skinned or intact fibers.  Warren et al. 
(134) found peak voltage-induced isometric force was reduced 69% after EDL muscle performed 
15 eccentric contractions in vitro, while maximal Ca2+ activated force produced by single fibers 
from these injured EDL muscles was only down by 34%.  These results indicate that damage to 
force bearing proteins could account for ~50% of the immediate force deficits after injury (134).  
To the contrary, Balnave and Allen (6) reported ~80% of the strength loss was accounted by 
damage to force bearing structures within the fibers after eccentric exercise.  Warren et al. (135, 
136) suggested that these discrepancies may be due to the muscle fibers being stretched beyond 
non-physiological lengths (i.e. >130%), which may have predisposed the force bearing structures 
to overt damage.  Additionally, measures of fiber maximal Ca2+ activated force may 
overestimate how much damage the force-bearing structures contributed to strength loss.  This 
overestimation is due, in part, to the removal of lateral transmission of force to neighboring 
fibers in these single fiber preparations (55). 
 Damage to the force bearing structures within the fibers can account for a widely varying 
proportion of the strength loss.  However, several studies have documented strength deficits are 
greatest immediately and up to 3 days post-injury while a very small amount of histological 
damage is present at the light microscope level 2 to 4 days after injury.  Further, strength deficits 
are attenuated after exposure to maximally activating Ca2+ which strongly suggests other 
mechanisms may also be responsible for reductions in strength immediately after injury (74, 
134).   
 Failure to activate intact force generating structures after contraction-induced injury  
This category of mechanisms includes those resulting in failure of the excitation-contraction (E-
C) coupling process, a sequence of events linking the release of acetylcholine at the 
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neuromuscular junction to the release of Ca2+ from the SR (37).  E-C coupling failure, or E-C 
uncoupling, in response to exercise was first suggested by Davies and White (33) in the late 
1970s and early 1980s.  However, the relative contribution of E-C uncoupling to strength loss 
was not investigated until Warren and colleagues (138).  To determine how much E-C 
uncoupling contributes to strength loss, pharmacological agents (e.g., caffeine, 4-chloro-m-
cresol) are used that act to promote ryanodine receptor (RyR) opening and increase free cytosolic 
Ca2+ levels.  Therefore, force elicited during caffeine exposure would not be dependent on 
acetylcholine release, action potential conduction along the plasmalemma or T-tubules, or the 
communication of the depolarization induced conformation change in the dihydropyridine 
receptor (DHPR).  Thus, any reduction in caffeine elicited force would imply damage to the 
force bearing elements, decreased Ca2+ sensitivity and/or intrinsic SR dysfunction.    
 By isolating mice soleus muscle after 20 eccentric contractions, Warren et al. (138) 
demonstrated that caffeine elicited force of the injured muscles was not different from that of 
control muscles despite the fact that maximal isometric torque was down by 43% in the injured 
muscle vs. 4% for the controls.  These data suggest that E-C uncoupling could account for the 
majority of the strength deficits early after injury.  To further support this concept, Balnave and 
Allen (6) showed depressed levels of free cytosolic Ca2+ levels during tetanic stimulation in a 
single fiber preparation following eccentric contractions.  Furthermore, by adding caffeine to the 
bathing medium in fibers that lost moderate amounts of strength (28%), free Ca2+ concentrations 
increased to normal levels.  Ingalls et al. (57) reported similar results by demonstrating force 
from injured EDL muscle was ~50% down immediately and up to 3 days after injury.  Free 
cytosolic Ca2+ was also reduced by 25-45% compared to uninjured muscles during electrical 
stimulation.  By comparing forces elicited by pharmacological agents (i.e., caffeine and 4-chloro-
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m-cresol) to forces stimulated electrically, Ingalls et al. (57) further estimated that E-C 
uncoupling could account for 57-75% of the isometric strength loss in the first 5 days after 
injury, and concluded that the remaining strength deficits at these early time points would 
therefore be attributed to physical damage to the force producing structures and/or myofibrillar 
Ca2+ sensitivity. 
 The specific mechanisms involved in E-C uncoupling are currently being investigated, 
but likely involve several proteins and protein-protein interactions.  Warren et al. (140) found 
EMG amplitude in injured and uninjured muscles (i.e., muscles that were exercised 
concentrically) was depressed (~9%) to a similar extent after exercise and recovered by 24 hours 
even though strength was still significantly down in the eccentrically injured fibers.  
Furthermore, Ingalls et al. (58) found in vitro strength deficits were similar when the EDL was 
exposed to normal or high concentrations of potassium (which act to depolarize all membranes).  
These studies suggest normal plasma and T-tubular membrane function after injury 
demonstrating the ability to generate action potentials after eccentric exercise did not impact 
strength deficits.  DHPR and RyR number and sensitivity appear to be normal immediately after 
injury on the basis of receptor binding experiments (e.g., scatchard analysis) (59).  Further, 
Ingalls et al. (57) found RyR release rates were not significantly impaired after injury when 
measured using confocal laser scanning microscopic or fluorometric techniques.  However when 
measured with a Ca2+ minielectrode, a significant reduction (6%) in RyR release rates was 
detected.  Taken together these studies suggest eccentric contraction-induced skeletal muscle 
injury disrupts the communication between the DHPR and RyR, and also the intrinsic ability of 
the RyR to release Ca2+. 
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 The physical uncoupling between DHPR and RyR seen after injury would reduce 
voltage-gated SR Ca2+ release and subsequently reduce the number of actin-myosin cross-
bridges.  In order to better elucidate this physical uncoupling, Corona et al. (29) analyzed 
junctophilin 1 and 2 (JP1 & 2) content, proteins responsible for maintaining the apposition of the 
T-tubule and SR membranes, before and after a bout of eccentric or concentric contractions.  
Through the first 3 days, significant reductions were observed in JP1 (50%) and JP2 (35%) 
content after the eccentric exercise while no changes were seen after the concentric exercise.  
Regression analysis of JP1 and JP2 content indicated that loss of JPs after eccentric injury was 
significantly associated with early reduction in strength.  In addition to disruptions in JP1 and 
JP2 content, early strength deficits may also stem from reductions in RyR function mediated by 
ancillary binding proteins such as FKBP12.   
 FKBP12 is a 12 kDa protein that binds to the subunits of the RyR homotetramer (61) and 
stabilizes the closed state of the channel preventing channel opening to subconductance states 
(i.e., SR Ca2+ leak) (18).  Similar to JPs, FKBP12 content was disrupted after eccentric exercise 
and not concentric exercise.  Baumann et al. (10) observed a 43% decrease in FKBP12 content in 
the pelleted fraction of mouse tibialis anterior (TA) muscle immediately after exercise which 
correlated with strength deficits after injury.  The fact that both JPs (29) and FKBP12 (10), two 
proteins known to be involved in SR Ca2+ release, are reduced after injury and associated with 
early strength deficits lends further support to the notion that E-C uncoupling is a major factor 
contributing to loss of function after contraction-induced skeletal muscle injury. 
 Loss of force generating structures after contraction-induced injury 
The initial damage to the force bearing structures is preceded by a marked increase in protein 
degradation rates between 1 and 5 days post-injury.  The marked increase in proteolysis is likely 
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due to several mechanisms including activation of calpains (11, 12), the ubiquitin-proteasome 
pathway (4, 123) and the inflammatory response (74).  Lowe et al. (74) suggests that these 
degradation pathways, specifically the inflammatory response, play a key role in removal of 
damage proteins before regeneration ensues.   
 In order to determine if there was a relationship between myofibrillar content and peak 
isometric force, Ingalls and colleagues mice (56) measured EDL force and myosin heavy chain 
(MHC) and actin following injury.  Through the first 3 days, no alterations were seen in total or 
myofibrillar protein content nor the amount of MHC or actin.  By day 5, total and myofibrillar 
protein content was significantly reduced (56) and remained down until day 14 (56, 74).  In 
parallel MHC and actin were ~19% less than control muscle at day 5 and 21-22% less at day 14.  
Both total and myofibrillar protein content and MHC and actin returned to normal by day 28.  
Peak tetanic force was reduced 37-49% for up to 3 days after the injury and slowly returned in 
the following weeks (14 days, ~24%; 28 days, ~11%).  Because protein content was not altered 
within the first 3 days after injury, while force deficits were peaked, decreases in the EDL force 
producing capacity could not be accounted for by a loss of force generating proteins (i.e., MHC 
and actin).  However, by day 5, reductions in MHC and actin content could account for 58% of 
the force reduction and nearly all the decrements at days 14 and 28. 
 Together, these data suggest that because peak EDL force recovers at the same time 
MHC and actin content are declining, degradation of myofibrillar proteins is likely restricted to 
the initial sites of damage and therefore little to no unnecessary proteolysis occurs.  In addition, 
because E-C uncoupling has been shown to explain some of the strength deficits after eccentric 
injury (10, 29, 57, 135, 136, 138), recovery of the E-C coupling machinery may also explain the 
paradoxical force recovery while contractile proteins content was declining.  This concept has 
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been supported by recent research that reported E-C coupling proteins are significantly reduced 
early after injury and return to normal around the same time when muscular strength begins to 
recover (10, 29). 
 Destruction and loss of muscle fibers after trauma-induced injury 
Two popular traumatic injury models include the use of intramuscular injections of either a snake 
venom (e.g., cardiotoxin - a snake venom that disrupts membranes and induces tissue necrosis) 
or BaCl2 (which causes muscle depolarization and myofiber death by stimulating exocytosis 
while blocking Ca2+ efflux).  In response to these toxins, 75–90% of the muscle is destroyed 
when employed in a mouse model (106).  During the acute post-injury period (≤6 h), myofibers 
become hyalinized and vacuolated and their nuclei are pyknotic or lysed (Figure 2) (45, 106).  
Therefore, toxin- and chemical-induced injury models drastically reduce muscular function 
through the destruction and loss of the muscle fibers, similar to decline in MHC and actin 
content after eccentric-contraction induced injury, but on a much larger scale.  In this way, 
traumatic injuries are ideal for characterizing regeneration rather than the mechanisms behind the 
loss of function. 
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Figure 2. Morphological analysis following cardiotoxin-induced injury. 
Time periods 6-12 h post-injury (A-D) (45). 
 
Recovery and regeneration after skeletal muscle injury 
 Inflammatory response 
Following injury, the muscle fibers and infiltrating immune cells release several pro-
inflammatory cytokines such as  IL-1β, IL-6 and TNFα (76).  These cytokines increase the 
expression of adhesion molecules within the endothelium and allow for margination of 
neutrophils.  Further, these adhesion molecules release additional cytokines (IL-6 and IL-8) that, 
in turn, recruit additional neutrophils (14).  Accumulation of neutrophils occur in skeletal muscle 
within 2 hours, reach peak levels by 1 day post-injury and slowly decline back to control levels 
by day 7 (99, 100).  Infiltrating neutrophils degrade proteins by releasing proteases and remove 
cellular debris through phagocytosis.  In addition, neutrophils produce a host of cytotoxic 
substances, including reactive oxygen species (ROS), such as superoxide anions, hypochloride, 
and hydrogen peroxide (13, 16).  Furthermore, the cytokines IL-1β, IL-6, and TNFα may 
stimulate pathways that contribute to the activation of the enzyme NADPH oxidase, a key 
enzyme that initiates the ‘‘respiratory burst’’ and subsequent release of ROS (21, 31).  These 
ROS are thought to delay recovery and/or cause secondary damage and loss of force after the 
initial injury (124). 
 Macrophages, another population of immune cells, generally appear after the arrival of 
neutrophils.  Macrophages are divided into two subpopulations, ED1+ and ED2+ (21, 81, 112).  
The ED1+ macrophages are found in the damaged sites 1 day after neutrophil invasion and are 
activated by pro-inflammatory cytokines (TNFα and IL-1β) (51).  Similar to neutrophils, 
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activated ED1+ macrophages act as phagocytes and function to remove cellular debris (112), and 
release pro-inflammatory cytokines such as prostaglandins and IL-1β (104).  One to 5 day after 
contraction-induced injury in mouse muscle, Lowe et al. (74) demonstrated protein degradation 
rates were elevated and correlated with the infiltration of phagocytic macrophages, suggesting 
that the inflammatory response plays a key role in removal of damaged proteins before 
regeneration ensues. 
 After the clearance of ED1+ macrophages near the later stages of inflammation (e.g.,  ≥2 
days), ED2+ macrophages generally appear (21) and regulate tissue repair and regeneration.  
ED2+ macrophages locate to the extracellular matrix and do not enter damaged tissue (112), 
suggesting their primary role in tissue repair is through cell signaling and growth regulatory 
cytokine production such as fibroblast and insulin-like growth factors.  The release of these 
growth factors facilitate MPC differentiation and orchestrate intracellular signaling pathways 
associated with repair (21, 24). 
 Satellite cells (SCs) 
Skeletal muscle exhibits a great capacity for regeneration after various injuries and diseases, 
largely due to a population of skeletal muscle stem cells, termed SCs.  Under noninjured 
conditions, SCs are quiescent and located between the sarcolemma and the basal lamina of the 
myofiber (Figure 3) (79, 106).  In this state, SCs display low transcriptional activity and dense 
heterochromatin.  In response to cellular and extracellular signals (e.g., cytokines, mechanical 
stress) associated with muscle damage, SCs are activated and exit their quiescent state, 
proliferate, differentiate and migrate to the site of injury to repair or replace damaged muscle 
fibers by fusing together, fusing to existing muscle fibers, or both (48, 117).  Repaired and newly 
synthesized fibers can be identified by their centrally located nuclei (Figures 1 and 4). 
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Figure 3.  Location of SC in adult skeletal muscle. (A) Electron micrograph of adult skeletal 
muscle demonstrating the myocyte nucleus and the SC nucleus.  (B) Schematic of (A) 
emphasizing that the SC lies between the basal lamina (black arrowhead or green line) and the 
sarcolemma (white arrowhead or red line) (106). 
 
 Satellite cells (SCs) are activated and begin to proliferate during the early phases of 
inflammation.  As the inflammatory response decreases, differentiation of SCs proceeds and 
ultimately the healthy myofiber population is reconstituted.  Otis et al. (96) demonstrated this 
process in the TA muscle of mice after BaCl2-induced injury.  One day after injury, the TA 
muscles showed edema and loss of myofiber content.  By 5 days of regeneration, the 
inflammatory response was reduced, the muscles were less edematous, macrophages had invaded 
the myofibers and the SCs were in a proliferative state.  Furthermore, numerous small basophilic, 
central-nucleated myofibers (i.e., newly regeneration myofibers) were visible.  By 10 days post-
injury, regenerating myofibers increased in size and continued to enlarge through day 28 when 
regeneration was essentially complete (96).  A similar coordinated response occurs after freeze 
and eccentric contraction-induced skeletal muscle injury (139). 
 Rathbone et al. (101) demonstrated the critical importance of SCs on recovery by 
exposing mice anterior crural muscle to irradiation and documenting recovery of torque up to 35 
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days after 150 eccentric contractions.  Interestingly, irradiated and nonirradiated muscular 
strength recovered at the same rate through 7 days demonstrating recovery of strength during the 
first week after contraction-induced injury does not require SC proliferation.  By 28 days into 
recovery, nonirradiated muscular torque recovered while torque was depressed 21-25% in the 
irradiated muscle through day 35.  Rathbone et al. (101) concluded that the SC dependent portion 
of strength recovery occurs 1-2 weeks post-injury and most likely resulted from a restoration of 
contractile protein and increased protein synthesis that requires SC to proliferate and presumably 
to mature and fuse with injured myofibers.  
 
 
Figure 4.  Centrally located nuclei – depicted by dark dots within the fibers. 
 
 Mammalian target of rapamycin complex 1 (mTORc1)  
The mammalian target of rapamycin complex 1 (mTORc1) plays a vital role in controlling 
protein synthesis rates (133).  mTORc1 has been implicated in muscle hypertrophy (15), and in 
recovery from freeze-(83) and toxin-(42) induced injury models.  mTORc1, a serine/threonine 
kinase, coordinates muscle regeneration and growth by phosphorylating p70s6k and the 
translation repressor 4EBP1, two proteins known to affect mRNA-binding steps during 
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translation (49, 133).  Baumann et al. (unpublished data) recently demonstrated that both 
mTORc1 and p70s6k activity significantly increased 3 days after eccentric injury.  Furthermore, 
by inhibiting mTORc1 and p70s6k with daily treatment of rapamycin, long-term strength deficits 
were exacerbated by ~20% and delayed the recovery of peak isometric torque.  These results 
provide further support that the mTORc1 pathway is activated after damage and instrumental to 
the recovery of muscle function following injury. 
 Heat shock proteins (Hsps) 
Heat shock proteins are vital to regeneration in injured, atrophied, and aged skeletal muscle.  
Heat shock proteins are a family of proteins that serve diverse roles that include chaperoning, 
assisting in the removal of damaged proteins, protein folding and transport, regulating cell 
signaling pathways, and protecting against cellular stress.  Because of these roles, Hsps are 
thought to restore protein homeostasis and contribute to cell survival (50, 66, 70).  
 
Skeletal muscle Hsps 
The term ‘heat shock protein’ was first coined in 1974 (127), but their discovery was over a 
decade earlier by Ritossa (102) in drosophila melanogaster larvae.  Heat shock proteins occur in 
all organisms and appear in both prokaryotic and eukaryotic cells, while displaying a high level 
of conservation.  Several different forms of Hsps exist and therefore are categorized into families 
on the basis of their molecular weight.  For this reason, the Cell Stress Society International has 
developed nomenclature to describe the protein family and the specific protein, with HSP 
referring to the protein family and Hsp to the specific protein. 
 Heat shock proteins range in molecular mass from 8 to 110 kDa and can be found in the 
cytosol, mitochondria, endoplasmic reticulum and nucleus.  In skeletal muscle, the most 
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abundant Hsps are small Hsps, HSP70, Hsp60 and HSP90.  Small Hsps range in molecular mass 
from 8 to 27 kDa and include ubiquitin, Hsp20, Hsp25, Hsp27 and alpha B-crystallin (70).  
These small Hsps facilitate the targeting and removal of denatured proteins (22), stabilize 
microfilaments and cytokine signal transduction (88), and facilitate protein refolding and muscle 
development (59).  Hsp60 is a mitochondrial Hsp responsible for folding and the assembly of 
proteins as they enter the mitochondria.  Hsp60 also stabilize mitochondrial proteins under stress 
(78).  Like other Hsps, HSP90 folds proteins, but are also thought to regulate the activity of 
steroid hormone receptors (32).  HSP70 consists of four major Hsps: Hsp72, Hsp73, Hsp75 and 
Hsp78.  Hsp75 and Hsp78 are termed GRP75 and GRP78, and are activated by glucose 
deprivation, calcium influx or agents that perturb glycolysis (72).  Hsp73, also termed heat shock 
cognate (Hsc73), is synthesized in most cells and is constitutively expressed in the cytoplasm 
under unstressed conditions.  Upon stress, Hsp73 translocates to the nucleus where it facilitates 
reintegration of denatured or unfolded pre-ribosomes (140).  Unlike the other Hsps, Hsp70 (also 
known as Hsp72) is highly inducible and is synthesized in response to multiple stressors (70).  In 
the unstressed state, Hsp70 is barely detectable.  But with significant cellular stress, Hsp70 
content rapidly increases and can constitute up to 20% of the total protein content (36).  For this 
reason, Hsp70 and its function in skeletal muscle will be the focus of this review.   
 
Structure and Regulation of Hsp70 
Hsp70 is a highly conserved protein composed of three domains, the N-terminal ATPase domain, 
a peptide-binding site and C-terminus (Figure 5).  Hsp70 shares a high correspondence of its 
amino acid residues with several different species (131).  Human Hsp70 is 73% identical to the 
drosophila protein and 50% identical to the E coli dnaK product (69). 
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Figure 5. Schematic illustration of the molecular structure of Hsp70 (70). 
 
 Hsp70 content is regulated by heat shock factor 1 (HSF1), a transcription factor that is 
bound to Hsp70 in the unstressed state.  In the bound state, Hsp70 and HSF1 are both inactive.  
Upon stress (e.g., elevated temperature, oxidative stress, contraction related stress, changes in 
energy metabolism, induction of stress related messengers and/or disturbances in oxygen 
perfusion and transport) cellular proteins unfold allowing hydrophobic regions of the peptide to 
be exposed.  These hydrophobic regions attract Hsp70 causing it to disassociate with HSF1.  
Further, the presence of denatured proteins stimulates the ATPase activity on Hsp70 resulting in 
the hydrolysis of ATP to ADP.  ATP hydrolysis increases Hsp70’s affinity for its substrate (i.e., 
denatured or unfolded proteins) which, in turn, stabilizes the Hsp70/ADP-substrate complex.  
Upon proper folding, Hsp70 exchanges ADP for ATP that reduces Hsp70’s affinity for its 
substrate, resulting in its release from the complex (70, 86). 
 When Hsp70 is bound to ADP in complex with its substrate, free HSF1 monomers 
become phosphorylated by protein kinase C or other serine/threonine kinases.  They then form a 
DNA binding homo-trimetric structure that is free to translocate into the nucleus.  In the nucleus, 
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the active HSF1 trimers bind to short nucleotide sequences on DNA promoter sites of the Hsp70 
gene, called heat shock elements.  This binding results in increased transcription of Hsp70 and 
subsequently Hsp70 protein content.  Increased levels Hsp70 provide aid and protection to the 
cell decreasing the number of denatured proteins.  At this point, the free Hsp70s rebind HSF1 
preventing further expression of Hsp70 (Figure 6) (70, 86). 
 
 
Figure 6.  Summary of the pathway involved in Hsp70 synthesis (66).  
 
General functions of Hsp70 in skeletal muscle 
 Intracellular molecular chaperone 
Newly synthesized peptides probably do not fold instantly; but rather they are assisted at the 
ribosome by molecular chaperones (i.e., heat shock proteins).  Molecular chaperones, such as 
Hsp70, are proteins and protein assemblies that help other proteins fold into their proper native 
conformation.  As mentioned above, Hsp70 binds to the hydrophobic regions of denatured 
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proteins in attempts to repair the defective protein by giving it another chance to refold.  
Furthermore, by binding and thus covering the hydrophobic regions of these proteins, Hsp70 
temporarily prevents denatured proteins from aggregating (1). 
 Stress sensor 
Hsp70 also plays a pivotal role during cellular stress that may occur due to elevated temperature, 
oxidative stress, contraction related stress, changes in energy metabolism, induction of stress 
related messengers and/or disturbances in oxygen perfusion and transport are all stressors that 
can unfold cellular proteins (Figure 6).  In response, Hsp70 content will increase to repair the 
unfolded proteins.  In parallel, Hsp70 prevents aggregation and degradation of unfolded proteins 
by the proteasomes.  
  Proteasomes are large protein complexes located in the cytosol and are responsible for 
degrading aberrant proteins.  Proteins destined for destruction are tagged with a small protein 
called ubiquitin.  If Hsp70 does not bind the unfolded protein before ubiquitin or Hsp70 is unable 
to repair it, the protein will be marked for degradation and transported to the proteasome.  The 
ubiquitin-proteasome can also facilitate degradation of newly synthesized proteins that are 
misfolded or contain abnormal amino acids (1). 
 Inhibitor of apoptosis  
Hsp70 inhibits apoptosis by acting on several steps both upstream and downstream of caspase 
activation.  The intrinsic pathway is characterized by the release of mitochondrial pro-apoptotic 
factors into the cytosol, while the extrinsic pathway is triggered by external signaling factors that 
induce the apoptotic process.  Siu et al. (109) investigated apoptotic adaptations from exercise 
training in skeletal muscle and found that exercise decreased Bax mRNA levels (pro-apoptotic 
signaling) and increased Bcl-2 (anti-apoptotic signaling).  Furthermore, Siu et al. (109) reported 
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that Hsp70 content was negatively correlated to Bax mRNA and caspase-3 activity and 
positively correlated to Bcl-2 mRNA and protein content.  The inhibitory potential of Hsp70 
over apoptosis occurs through many signaling mechanisms (e.g. JNK, NF-κB and Akt), which 
are directly or indirectly blocked by Hsp70, or through increased Bcl-2 protein content.  These 
mechanisms are thought to be responsible for Hsp70’s anti-apoptotic function in cells under 
stressful conditions (103). 
 Inhibitor of nuclear factor-κB (NF-κB) 
Nuclear factor-κB (NF-κB) is a dimeric transcription factor that regulates a broad range of 
biological processes, including innate and adaptive immunity, inflammation, stress responses, B 
cell development and apoptosis.  NF-κB signaling is regulated by binding with inhibitor of kappa 
B (IκB) proteins (43).  In the presence of known inducers of NF-κB (e.g., ROS, IL-1β, TNFα) 
(23, 43), IκB is phosphorylated by IκB kinase (IKK) resulting in the release of IκB.  Free NF-κB 
translocates to the nucleus and increases gene expression of numerous chemokines and 
cytokines, many of which are the same proteins that initially activated it (Figure 7) (43).  
Increased Hsp70 content and heat shock treatment are known to inhibit NF-κB activity (35, 82, 
95, 107), likely mediated through increased levels of IκBα (35, 95) that retain NF-κB proteins in 
cytosol preventing gene expression of inflammatory cytokines.  It therefore has been suggested 
that Hsp70 may exert an anti-inflammatory effect in skeletal muscle. 
 
 Figure 7. 
Changes in Hsp70 content 
 Eccentric contraction-induced
Eccentric exercise is known to be a strong inducer of Hsp70
increased 4.27 fold in mouse TA muscle 
Further, Hsp70 was elevated 6 h 
declined up to 14 days following injury 
paralleled, by reductions in intramuscular MHC and actin, suggesting a relationship between 
myofibrillar proteolysis and Hsp70 induction 
contractions resulted in large strength deficits that remained reduced for several days.
 Eccentric exercise has also 
122, 130, 141).  Following a single bout of a 30 min of bench
Hsp70 expression in the vastus lateralis was increased at 3 (8.9 fold) and 24 (1.8 fold) hours 
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Depiction of the NF-κB pathway. 
 
 alterations to Hsp70 
 (7, 56).  Expression of Hsp70 
48 h after a bout of 50 eccentric contractions 
post-injury, peaked between 1 and 5 days, and gradually 
(56).  The changes in Hsp70 were accompanied, but not 
(56).  In both studies (7, 56), the bout of eccentric 
been shown to up-regulate Hsp70 in human muscle
-stepping at 60 steps per minute, 
 
(7).  
 
 (98, 120-
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post-exercise, after which it declined to baseline levels 7 days into recovery (130).  Willoughby 
et al. (141) reported similar finding in the vastus lateralis, demonstrating Hsp70 mRNA and 
protein content increased 97% and 128%, respectively, 48 h after eccentric exercise of the knee 
extensors (11).  Further, Hsp70 content was found to be 227-1065% higher in the biceps brachii 
48 h after resistance exercise (2 sets of 25 repetitions) with the elbow flexor muscles (7, 8).  
Paulsen et al. (98) recently demonstrated that increased Hsp70 content is also location specific.  
For example, Hsp70 content in the cytosolic fraction tended to be lower in the injured muscle 30 
min after exercise but increased thereafter and was 203% higher 24 h after exercise.  In contrast, 
Hsp70 content in the myofibrillar fraction was elevated by ~2 fold at 0.5 h and ~10 fold at 96 h 
post-injury.  
 Pharmallogically-induced alterations to Hsp70 
Altering Hsp content with pharmaceuticals was initially developed for cancer therapies (111), 
but has extended to skeletal muscle injury models over the past decade (27, 63).  Two drugs that 
have received recent attention are radicicol (27, 84) and 17-allylamino-17-demethoxy-
geldanamycin (17AAG) (63).  Both drugs are Hsp90 inhibitors and prevent association with 
HSF1.  Then, HSF1 is free to translocate to the nucleus and subsequently increase the expression 
of Hsp40, Hsp70 and Hsp90 (111). 
 Radicicol is a natural product with antibiotic, antifungal, and antimalarial properties.  
When radiciol is administered intramuscularly (0.05 mg/20 g) into the hindlimb of mice there is 
a marked increase in Hsp70 1 day after administration (27, 84).  The increase in Hsp70 was 
found to be similar to that of mice genetically overexpressing Hsp70 from birth (27).  
Alternatively, 17AAG, a derivative of the antibiotic geldanamycin, can also increase Hsp70 in 
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mice (63, 73).  Intraperitoneal (ip) injections of 17AAG ( 40 mg/kg) significantly increased EDL 
Hsp70 for up to 10 days after treatment, with content increased 218% at day 3 (63).  
 Genetically-induced alterations in Hsp70 
McArdle et al. (20, 80) found a 10-20 fold increase in Hsp70 in the EDL and TA at rest of 
transgenic mice.  However, overexpression of Hsp70 in the skeletal muscles reduced body mass 
by ~10% and muscle mass by ~20% (80).  To prevent the large increase in Hsp70 content in 
transgenic mice, which may not be physiologically attainable, and any other alterations that may 
occur from genetic manipulation from birth, Senf et al. (105)  and Dodd et al. (35) transduced rat 
soleus muscle with an Hsp70 expression plasmid to specifically overexpress Hsp70.  This 
transduction caused an approximately 2.5 to 5-fold increase in Hsp70 protein expression over 
endogenous levels (35, 105). 
 Heat-induced alterations in Hsp70 
Heat shock proteins (Hsps) can be increased by heat shock treatment.  Heat shock treatment can 
be obtained through the use of warm-hot water (46, 128) or air temperature (64, 108).  By 
supporting rats in a hot water bath at 43°C (core 41 and 41.5°C) for 20 min (46, 128), Hsp70 
expression increased, peaking at 48 h in the soleus muscle (128).  Similarly, placing rats in a 
heated chamber (ambient temperature, 42 ± 1.0°C) for 60 min resulted in similar elevations in 
Hsp70 expression (64, 108).  Immediately after heat shock treatment, Hsp70 mRNA expression 
significantly increased and stayed elevated for 3 days (108). 
Hsp70 reduces characteristics of skeletal muscle injury 
 Histological damage 
Elevated levels of Hsp70 attenuate histological damage and reduce phagocytic cells infiltration 
in injured muscles (63, 64, 80, 84, 108, 128).  Leukocyte infiltration after heat shock treatment 
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was significantly lower immediately, 2 and 7 days after rats exercised downhill for 60 min 
compared to control rats.  Furthermore, injured muscles that received heat shock treatment had 
fewer degenerated fibers 2, 3, and 7 days after exercise (108).  Similar findings have recently 
been reported by Touchberry et al. (128) who demonstrated that heat shock treatment before a 
downhill running protocol reduced the number of infiltrating mononuclear cells and the number 
of swollen fibers 2 days post-injury.  Heat shock treatment before or after cardiotoxin-induced 
injury reduced the inflammatory response and resulted in more newly formed myotubes 
compared to controls 7 days into recovery (64).  Additionally, by day 14 the diameter of the 
regenerating fibers was considerably larger in the heat-treated muscle.    
 Alternatively, transgenic mice overexpressing Hsp70 display similar protection against 
injury.  Three days after a bout of 450 eccentric contractions in situ, transgenic mice had a higher 
percentage of intact EDL fibers compared to wild-type mice that did the same injury protocol 
(80).  The same group later reported that using the drug 17AAG reduced the number of centrally 
positioned nuclei 28 days after 450 eccentric contraction in treated vs. untreated mice (22.5 vs. 
39.3%), indicating the muscle fibers regenerated quicker after 17AAG treatment (63).  Further, 
10 days after freeze injury, mice muscle overexpressing Hsp70 displayed less inflammation and 
larger fiber CSA compared to wild-type mice (84). 
 Blood creatine kinase (CK) levels 
Blood levels of CK are used to detect skeletal muscle inflammation (i.e., myositis) or damage.  
Heat shock treatment prior to injury reduced CK release in cell culture (75) and human skeletal 
muscle (110).  However, these studies did not document how heat shock treatment affected 
levels of Hsp70 and therefore, it is difficult to determine if the reduction in serum CK was due to 
an increase in Hsp70.  To confirm this, Touchberry et al. (128) heat shocked rat soleus muscle in 
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a water bath before a downhill running protocol and analyzed serum CK 2 and 48 hours after the 
exercise bout.  Heat shock treatment increased Hsp70 and significantly lowered levels of serum 
CK 2 hours after exercise compared to control treated rats.  By 48 hours CK levels returned to 
baseline levels in both groups (64).  Furthermore, heat shock treatment in rats prevented 
elevations in CK levels after cardiotoxin-induced injury (64). 
 Strength deficits 
Hsp70 is significantly increased after exercise (see above) and, therefore, may play a vital role in 
the recovery of strength following injury.  By injuring the quadriceps of male subjects through a 
single bout of 300 maximal voluntary eccentric contractions, Paulsen et al. (98) demonstrated 
that the number of Hsp70 positive fibers increased during the first 8 hours after injury and 
remained elevated for at least 7 days.  During the same period, maximal concentric torque at 
60°/s was reduced 47% immediately after exercise and remained down for the next 7 days.  By 
comparing peak levels of Hsp70 in the days after exercise and strength deficits immediately after 
the bout of 300 eccentric contractions, Paulsen et al. (98) concluded that with greater strength 
deficits more Hsp70 was synthesized, suggesting Hsp70 is involved in the remodeling/adaptation 
process in skeletal muscle. 
 In support of this, McArdle et al. (80) reported transgenic mice overexpressing Hsp70 
recovered significantly faster than their wild-type (WT) counter parts.  Three hours following a 
bout of 450 isolated eccentric contractions, WT and Hsp70 transgenic mice exhibited similar 
force deficits of 50–70%.  Between 3 h and 3 days, peak isometric torque of the WT mice 
showed a further decrease of ~20%, while no secondary loss of strength was evident in the 
Hsp70 mice.  By day 14, peak isometric torque in the Hsp70 mice was not significantly different 
than pre-injury torque.  In contrast, the WT mice still exhibited reductions of ~50% in peak 
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isometric torque.  Strength deficits were eliminated 28 days into recovery in the adult WT (i.e., 
10-12 months), and adult and old (i.e., 26-28 months) Hsp70 mice, but peak isometric torque 
remained 44% down in the old WT mice.  McArdle et al. (80) concluded that the rapid recovery 
of EDL strength of old mice overexpressing Hsp70 was remarkable considering old WT mice 
sustained large force deficits even after 28 days of recovery. 
 In attempt to mimic the protective effects of overexpressing Hsp70 in the transgenic 
mice, McArdle’s group (63) used an Hsp90 inhibitor to increase Hsp70 content in old WT mice.  
Treatment of 17AAG significantly increased Hsp70 muscle content for 10 days, with content 
peaking after day 1.  To determine if 17AAG could attenuate strength deficits after eccentric 
injury (i.e., 450 eccentric contractions), mice were injected 3 days before exercise and then after, 
every 7 days for up to 4 weeks.  Treatment of 17AAG was associated with significant 
improvements in recovery of force 28 days post-injury compared to the untreated mice.  In fact, 
peak isometric force generated by the  EDL muscle of 17AAG-treated mice returned to pre-
injury values while untreated EDL force remained ~50% down (63).  Their results (63, 80) 
indicate that pharmallogically increasing Hsp70 content shortly before eccentric exercise can 
expedite the recovery process in a similar fashion to that of Hsp70 overexpression using 
transgenic mice.  Though these studies reported that Hsp70 enhanced the functional return of 
strength following eccentric injury, they did not elucidate the mechanistic properties for Hsp70’s 
beneficial effects.  However, in both studies, histological damage and secondary injury were 
attenuated and prevented, respectively.  Because of these observations, the authors suggested 
Hsp70 may reduce the activity of  proteins and/or signaling pathways associated with oxidative 
stress and inflammation (63, 80).   
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Hsp70 facilitates recovery after injury 
 Protein folding and chaperone activity 
Hsp70 are chaperone proteins that refold denatured proteins and fold newly synthesized proteins 
and therefore are vital components involved in cellular repair.  Hsp70 is known to translocate to 
myofibrillar proteins after eccentric injury, suggesting it may be a stabilizer of the myofibrillar 
structure, refolding denatured contractile proteins before they irreversibly aggregate and 
denatured and are degraded (98).  Increased Hsp70 content in the myofibrillar fraction after 
exercise could indicate that Hsp70 plays a role in the assembly and incorporation of new proteins 
in the myofibrillar framework (98).  McArdle et al. (80) suggested that the concentration of 
Hsp70 may be the rate limiting factor of protein synthesis in skeletal muscle. 
 Protein synthesis: Intracellular signaling and SC activity 
One of the first observations that demonstrated heat shock treatment impacted protein synthesis 
and content in vivo was by Kojima et al. (64) in 2007.  They demonstrated that heat shock 
treatment before or shortly after a cardiotoxin injection resulted in significantly higher levels of 
TA muscle protein content 28 days into recovery than rats that did not receive heat shock 
treatment.  The heat-treated rats also exhibited fewer infiltrating mononucleated cells and had 
larger regenerating muscle fibers 2 weeks after the injury.  By day 28, the heat-treated rats had 
almost fully recovered while the untreated rats still presented small regenerating fibers (64).  
Touchberry et al. (128) recently confirmed the results of Kojima et al. (64) by analyzing total 
soleus muscle protein and MHC neonatal (MHCn) content 2 h and 2 days after heat-treated rats 
performed a downhill running protocol.  Two hours following exercise there were no differences 
in total protein content between heat-treated and untreated rats; however, 2 days after injury total 
protein content was higher in the heat-treated group compared to the untreated group.  
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Furthermore, at both time points, MHCn content was significantly higher in the heat-treated 
group (128).  Touchberry et al. (128) speculated that heat shock treatment prior to muscle 
damage increased protein synthesis, and/or prevented the loss of intracellular proteins following 
damage.  Preventing the loss of intracellular proteins may be mediated by stabilization of the 
sarcomeres by Hsp70 binding cytoskeletal/myofibrillar proteins (98) and ultimately stopping the 
global diffusion of proteins out of damaged myofibrils (128).  Alternatively, increased total 
protein and MHCn content may be orchestrated through intracellular signaling pathways and/or 
SC activity.  
 To assess changes in intracellular signaling, Touchberry et al. (128) analyzed Akt/p70s6k 
signaling and mitogen-activated protein kinases (MAPK) (i.e., ERK1/2/JNK), two signaling 
pathways involved in protein synthesis.  ERK1/2 activity 2 h after injury was significantly lower 
in the heat-treated rats, but returned to control levels by day 2.  No differences were observed 
between groups for Akt, p70sk6 and JNK at either time points (128).  Because heat shock 
treatment did not increase the activity of the Akt/p70s6k or MAPK pathways (128), an 
alternative mechanism is that heat stress and thus evaluated levels of Hsp70 increased SC 
activity (27, 64, 85, 95, 128).  In support of this, 3 days after heat shock treatment, the relative 
population of SCs at rest significantly increased in rat soleus muscle compared to control muscle 
(95).  Similar findings have been observed after injury (27, 64) and in atrophied muscle (85).  
Radicicol-treated mice had more satellite cells from 1 (31%) to 10 (63%) days after crotoxin 
injury compared to vehicle-treated mice (27).  Similarly, 3 days after cardiotoxin injury, SC 
activity in heat-treated rats was found to be significantly higher than untreated rats (64).  
Miyabara et al. (85) demonstrated that after 7 days of immobilization the number of SCs in 
mouse EDL and soleus muscle was reduced, and by overexpressing Hsp70 this reduction was 
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prevented.  Furthermore, Hsp70 muscle displayed centrally positioned nuclei and regenerating 
fibers earlier in recovery compared to controls.  Miyabara et al. (84) demonstrated that 10 days 
after cyrolesion, Hsp70 transgenic mice had fewer MHCn-positive cells than did wild-type mice, 
while Kayani et al. (63) reported that increased Hsp70 content reduced the number of centrally 
positioned nuclei 28 days after 450 eccentric contraction, indicative of complete recovery of the 
regenerating fibers.  Taken together, these results suggest that elevated levels of Hsp70 prior to 
injury may expedite the recovery process through increasing SC activity.   
 Inflammation and secondary damage 
Infiltration of phagocytes following injury is accompanied by an increased production of free 
radicals and lipid and protein oxidation.  Free radicals, specifically ROS, are primarily produced 
by activated neutrophils shortly after injury.  Neutrophils orchestrate repair by removing cellular 
debris, but can also damage the fiber if excess ROS and proteases are released (13, 21, 124).  
This secondary damage or injury can delay the muscle’s regenerative capabilities and increase 
strength deficits in the days following the initial exercise bout.  Pizza et al. (99) suggested that 
ROS may exacerbate pre-existing muscle injury by damaging previously uninjured muscle.  
Several reports have demonstrated that increased Hsp70 levels reduce the number of phagocytic 
cells infiltrating (108, 128) the injured muscle fibers and the amount of fiber swelling (128) after 
injury.  Elevated levels of Hsp70 may also protect the fibers from an unnecessarily strong 
inflammatory process (i.e., excess ROS and protease production) that can cause secondary 
damage (80, 98, 108, 129) and delay recovery. 
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Proposed mechanisms by which Hsp70 enhances recovery 
 Hsp70 content inhibits NF-κB signaling  
It is currently unknown how Hsp70 content enhances recovery after injury, however previous 
research would suggest there is a link between Hsp70 and the NF-κB pathway.  As mentioned 
previously, the activity of NF-κB is primarily regulated by its interaction with inhibitory IκB 
proteins.  Inactive NF-κB is sequestered in the cytoplasm by the IκBα protein (19, 43). Upon 
receiving a multitude of extracellular signals, IκB proteins are phosphorylated, ubiquitinated, and 
targeted to the proteasome for degradation (43, 143).  NF-κB is dissociated from the IκB 
inhibitory proteins and then translocated to the nucleus leading to transcriptional activity.  NF-κB 
is a major pleiotropic transcription factor modulating inflammation (43, 107).  Proteins of 
particular interest that are transcribed by NF-κB include IL-1β, IL-6, and TNFα.  Importantly, 
these proteins are known to orchestrate neutrophil and macrophage infiltration, SC activity and 
regulate NF-κB signaling (Figure 7).  
 Although, Hsp70 has been shown to inhibit NF-κB signaling, the specific details and 
models remain to be explored.  Ohno et al. (95) demonstrated that heat shock treatment resulted 
in increased IκBα and decreased phospho-NF-κB content.  Furthermore, several studies have 
shown that deceased NF-κB activity is caused by the upstream increase in Hsp70 (82, 107, 142).  
Heat shock treatment in BEAS-2B cells, a human bronchial epithelium cells, increased 
expression of IκBα mRNA and subsequently inhibited NF-κB (142).  Meldrum et al. (82) 
reported liposomal transfer or thermal induction of Hsp70  prevented NF-κB activation and 
translocation to the nucleus in renal tubular cells.  Furthermore, in a macrophage cell line, 
overexpression of Hsp70 inhibited the nuclear translocation of p65, the transcriptionally active 
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component of the NF-κB complex, and prevented the degradation of IκBα (107).  More recently, 
it was reported that overexpression of Hsp70 in rats increased IκBα levels and prevented an 
increase in NF-κB activity that is associated with immobilization (35).  Taken together, these 
findings suggest that Hsp70 may inhibit NF-κB activity through increasing the levels IκBα that 
are available to bind and retain NF-κB in the cytosol.  
 NF-κB gene products are also inhibited by Hsp70.  For example, Meldrum et al. (82) 
reported that liposomal transfer or thermal induction of Hsp70 prevented TNFα gene 
transcription.  Similarly, Shi et al. (107) demonstrated Hsp70 overexpression could inhibit 
TNFα, as well as other pro-inflammatory cytokines like IL-1.  In rat soleus muscle, heat shock 
treatment reduced TNFα content after 3 days (95).  Importantly, this decrease in TNFα was 
observed following an increase in Hsp70 and a decrease of phospho-NF-κB content.  Because 
up-regulation of Hsp70 prevents IL-1 and TNFα gene transcription (82, 107) and NF-κB 
activation synthesizes these pro-inflammatory cytokines (43), inhibition of IL-1and TNFα is 
likely mediated through reduced NF-κB activity (95). 
 Role of NF-κB in inflammation 
NF-κB signaling leads to the production of cytokines (e.g. IL-1β, IL-6, and TNFα) that 
orchestrate the inflammatory response.  Inflammation increases neutrophil and macrophage 
accumulation in the cell.  Neutrophils produce a host of cytotoxic substances, including ROS, 
such as superoxide anions, hypochloride, and hydrogen peroxide (13, 16).  Furthermore, the 
cytokines IL-1β, IL-6, and TNFα may all stimulate pathways that contribute to activation of 
NADPH oxidase, a key enzyme that initiates the ‘‘respiratory burst’’ and subsequent release of 
ROS (21, 31).  Though neutrophil activation leads to beneficial proteolysis and removal of 
debris, they can also release high concentrations of cytolytic and cytotoxic molecules (e.g. 
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proteases, ROS) that can damage healthy muscle (125).  Whether a positive or negative response 
will prevail depends on many variables such as, the site of ROS production, persistence of ROS 
flow and the cell’s antioxidant status.  Prolonged, severe oxidative stress may imbalance 
intracellular antioxidant homeostasis and overall muscle health (8).  High levels of ROS cause 
functional oxidative damage to proteins, lipids, nucleic acids and cell components, induce a 
significant rise in intracellular Ca2+ concentration and promote signaling cascades for apoptosis 
or autophagy via NF-κB or FoxO pathways (8).  For these reasons, high ROS levels are often 
contributing factors in muscle degeneration, atrophy, sarcopenia, wasting, and chronic muscle 
diseases.  Recent evidence has shown that administration of an antibody that blocks the 
“respiratory burst” and degranulation of neutrophils prior to lengthening contractions also 
produces large reductions in microscopically discernable muscle damage (17). 
 With injury, excessive inflammation and ROS production is thought to cause secondary 
damage and loss of force (124).  Together with antioxidants, Hsp70 may mediate this process by 
protecting the cell against oxidative stress (71, 98) and reducing levels of pro-inflammatory 
cytokines (58) and ROS through inhibition of NF-κB signaling (35, 82, 105, 107).  In parallel, 
leukocytes infiltration was abated in muscle overexpressing Hsp70 or muscle that received heat 
shock treatment prior to injury (108, 128).  Hsp70 may also facilitate recovery through increased 
ROS scavenger/antioxidant activity within the fiber (84, 108).  Specifically, superoxide 
dismutase activity was increased 3 days after heat-treated rats preformed eccentric exercise 
(108).   Further, glutathione peroxidase activity was found to significantly higher 10 days after 
freeze-injury in mice overexpressing Hsp70 compared with muscles of wild-type mice (84). 
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 Role of NF-κB in regulating myogenesis 
Differentiation of SCs into myotubes is a fundamental prerequisite for muscle regeneration.  NF-
κB is associated with a negative regulation of skeletal muscle differentiation (47, 68, 132).  NF- 
κB is thought to reduce myogenesis by inhibiting the synthesis of MyoD, a muscle-specific 
helix-loop-helix transcription factor central to muscle development and repair (47).  In addition, 
NF-κB is able to suppress myofibrillar gene expression through the regulation of the myogenic 
transcriptional repressor Yin Yiang 1 (YY1) (132).  In skeletal muscle, YY1 is considered to 
play a negative role in myogenesis by directly repressing the synthesis of late-stage 
differentiation genes, including skeletal actin, muscle CK and MHCII.  In support of these 
findings, treatment of primary myoblasts with the NF-κB inhibitor curcumin stimulated myoblast 
fusion and enhanced myogenesis and repair, characterized by increased expression of MHCe 
after freeze-induced injury in mice (118).  Similarly, 10 days after cardiotoxin-induced injury, 
mouse muscle depleted of NF-κB signaling (IKK knockdown mice) showed improved 
morphology, reduced intracellular space, and larger size of new myofibers compared to wild-
type mice.  Furthermore, fiber size and strength were preserved as late as 28 days after 
denervation, while wild type mice were not protected against atrophy (89).    
 Additionally, TNFα, one of inflammatory cytokines synthesized by NF-κB activation, 
can suppress SC differentiation (34, 67) through the inhibition of the myogenic regulatory factors 
MyoD and myogenin (115).  TNFα activates NK-κB creating a positive feedback loop resulting 
in increased pro-inflammatory cytokine production and further inhibition of myogenesis, but also 
an increased production of ROS.  Prolonged elevations in ROS mediated through neutrophils 
may cause further injury through oxidative damage and delay SC differentiation (8, 124).  Ardite 
 37 
 
et al. (2) showed that ROS depleted intracellular glutathione which caused further intracellular 
accumulation of ROS.  The elevated ROS levels favor NF-κB activation and reduce the 
expression of MyoD impairing myogenesis.   
 
Working hypothesis 
 
Skeletal muscle is a force producing tissue that is required for locomotion, metabolism, 
generating heat and the maintenance of posture.  Upon injury, the muscle’s functional capacity is 
diminished and its return is dependent on the ability of the muscle to undergo remodeling.  This 
remodeling occurs through a coordinated inflammatory response that includes SC activation, 
proliferation and differentiation followed by muscle growth (48, 124).  Numerous transcription 
factors, such as NF-κB, regulate these inflammatory and myogenic processes (5).  For example, 
NF-κB is activated by pro-inflammatory cytokines (e.g. TNFα) and ROS that are produced and 
released by the injured muscle or invading leukocytes (97).  TNFα acts as a mitogen in muscle 
proliferation (96), but also as a negative regulator of differentiation (67).  Furthermore, TNFα 
increases ROS production, which in excess inhibits myogenesis (8, 119).  Following injury, 
sustained NF-κB signaling is thought to blunt skeletal muscle regeneration (8).  For this reason, 
many therapeutic trials have used NF-κB inhibitors to ameliorate muscle recovery following 
injury or disease (90). 
 The drug 17AAG, a Hsp90 inhibitor (111), increases Hsp70 content in vitro (63) and in 
vivo (63, 73).  Recently, treatment of 17AAG has been reported to improve recovery following 
contraction-induced injury in old muscles (63) and attenuate atrophy following unloading (73).  
Hsp70 is known for its role as a molecular chaperone (50, 70), but the beneficial effects observed 
in these recent studies are likely mediated by other means.  By increasing Hsp70 through heat 
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shock treatment, genetic manipulation or the use of pharmaceuticals, several investigators have 
documented reductions in NF-κB activity (35, 82, 95, 105, 107, 142) and TNFα content (82, 95, 
107), and enhanced SC (27, 64, 85, 95, 128) and ROS scavenger/antioxidant activity (84, 108).  
However, how Hsp70 content stimulates skeletal muscle regeneration has not yet been explored.  
Therefore, the purpose of this study will be to: (1) determine the effects of 17AAG on 
histological alterations and functional deficits following muscle injury and, (2) quantify the 
effects of 17AAG on NF-κB activity, NF-κB-dependent signaling components and 
ROS/antioxidant levels (Figure 8). 
 
 
Figure 8. Proposed mechanisms by which 17AAG (G) improves muscle regeneration. 
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2 HEAT SHOCK PROTEIN 70 REGULATES TUMOR NECROSIS FACTOR 
ΑLPHA AND MYOGENIN IN SKELETAL MUSCLE FOLLOWING 
CHEMICAL-INDUCED INJURY 
 
Introduction 
 
Skeletal muscle is required to sustain life and is involved in daily tasks such as locomotion, 
movement and the maintenance of posture.  These tasks are achieved through the muscle’s 
capacity to produce force, which is dependent upon the number of sarcomeres acting in parallel 
and the force generated per sarcomere.  Following chemical or toxin-induced injury, ~70-90% of 
the afflicted myofibers are lost or lysed (47, 57), drastically reducing the muscle’s ability to 
produce force.  Reductions in force have been reported to be over 90% in mouse skeletal muscle 
and take several weeks to fully recovery (9).  The return of strength, and thus function, is 
dependent on the muscle’s ability to regenerate, a highly coordinated process that involves 
inflammation, degeneration of damaged myofibers and the formation of new myofibers (i.e., 
myogenesis) (47, 52, 53).   
 The inflammatory response begins shortly after the injury, coincident with the influx of 
phagocytic neutrophils and macrophages.  These inflammatory cells, mainly macrophages, 
facilitate muscle regeneration through phagocytosis of cellular debris and the release of soluble 
factors, including chemoattractants, growth factors and cytokines (52, 53).  Of particular interest 
is TNF-α, a cytokine that peaks 1-3 days post-injury (10, 56, 58) during both the inflammatory 
and subsequent myogenic phases of recovery, suggesting TNF-α has a binary role in skeletal 
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muscle regeneration (9, 10, 53, 56).  Classically portrayed as a pro-inflammatory mediator, TNF-
α activates NF-κB inducing TNF-α transcription, further promoting NF-κB activity and thus 
inflammation (22).  However, TNF-α also acts as a mitogen increasing satellite cell activation 
and proliferation (33, 43, 50).  The impact of TNF-α on myoblast differentiation appears to be 
more complex, with some reporting TNF-α stimulates p38 MAPK activating key differentiation 
mediators including myocyte enhancer factor (MEF)-2, myogenin and the Cdk inhibitor p21, and 
suppression of cyclin D1 (9, 10), while others demonstrate TNF-α inhibits differentiation by 
destabilizing MyoD mRNA and degrading the MyoD protein (24, 30, 31, 50).  These 
contradictory findings likely reflect the concentration of and persistence at which TNF-α remains 
in the microenvironment (10).  Despite considerable efforts to understand the mechanisms that 
control skeletal muscle regeneration, the complete profile of intrinsic and extrinsic cues that 
mediate TNF-α expression remain unknown.   
 Heat shock protein 70 (Hsp70, so-called Hsp72) also responds to skeletal muscle trauma 
and increases several fold shortly following skeletal muscle injury (16, 25, 51).  Induction of 
Hsp70 mediates skeletal muscle mass, regeneration and function, and therapies targeting Hsp70 
have proven beneficial in animal models of skeletal muscle atrophy, aging and injury (44).  
These beneficial effects are, in part, due to its role as a molecular chaperone, refolding denatured 
proteins and controlling protein quality (38).  In addition, Hsp70 also regulates the activity of 
various transcription and signaling factors, including NF-κB and TNF-α (4, 5, 37, 39, 48).  Some 
evidence suggests that Hsp70 initiates the inflammatory response (1, 2, 21, 46) by activating 
neutrophils (23, 40), macrophages and peripheral blood monocytes (3, 4, 28) increasing TNF-α 
expression (4, 5).  Conversely, Hsp70 has also been reported to increase levels of IκBα (15, 39), 
an NF-κB inhibitor, thereby decreasing NF-κB activity (15, 37, 39, 48) and TNF-α expression 
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(37, 39, 48).  These divergent findings are likely due to variability in experimental designs, 
including the type of cell line or tissue examined, the methods used to manipulate Hsp70 (e.g., 
heat shock treatment, genetic manipulation, pharmaceuticals) and when skeletal muscle is 
targeted, the type of stress or insult imposed on it (e.g., hindlimb unloading, injury, aging).  
Nonetheless, because TNF-α and Hsp70 expression increase shortly following insult and 
knowing skeletal muscle regeneration is dependent on inflammation and myogenesis, it is 
difficult to reconcile why Hsp70 would inhibit TNF-α expression, particularly following skeletal 
muscle injury.   
 Therefore, we sought to determine if the pharmaceutical 17-allylamino-17-demethoxy-
geldanamycin (17-AAG), a known stimulator of Hsp70, would alter TNF-α content following 
skeletal muscle injury induced by an intramuscular injection BaCl2.  An intramuscular injection 
of BaCl2 produces damage similar to that of snake toxins in which degeneration and 
inflammation develop more quickly than other types of injury (32), thereby amplifying TNF-α 
signaling.  Next, we evaluated the relationship between TNF-α and myoblast differentiation by 
analyzing myogenin content.  Finally, to determine if these molecular markers of regeneration 
have any measureable impact on muscle structure and function, we assessed regenerating fiber 
cross-sectional area (CSA) and in vivo torque deficits following the BaCl2-induced injury.  We 
hypothesized treatment of 17-AAG would increase TNF-α and myogenin content above that of 
the injured control muscle in the days following the injury, thereby enhancing both skeletal 
muscle regeneration and function. 
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Methods 
Animals 
Male C57BL6 mice ~2-4 months old were used in this study.  Mice were housed in groups of 5 
animals per cage, supplied with food and water ad libitum, and maintained in a room at 20–22°C 
with a 12-h photoperiod.  The mice were euthanized with an overdose of isoflurane followed by 
cervical dislocation.  All procedures were approved by the Georgia State University Institutional 
Animal Care and Use Committee and met the guidelines set by the American Physiological 
Society. 
Experimental design 
Mice were randomly assigned to one of two groups: vehicle-treated or drug-treated.  The 
vehicle-treated (i.e, control) group received intraperitoneal (i.p.) injections of dimethyl sulfoxide 
(DMSO; Sigma, St Louis, MO), while the drug-treated group received i.p. injections of 17-AAG 
(LC Laboratories, Woburn, MA) at a dose of 40 mg/kg body weight in 100 µl of DMSO.  This 
dose of 17-AAG and route of delivery has been shown to result in 99% bioavailability of the 
drug in skeletal muscle (19).  Treatment of DMSO or 17-AAG began 3 days prior to a BaCl2-
induced injury to the left tibialis anterior (TA) muscle.  Following this initial dose, mice 
continued to receive treatment every 7 days for up to 3 weeks as previously described (26).  
Thus, injections occurred 3 days prior, and 4, 11 and 18 days post-injury.   
 One in a half, 3.5, 7, 14 or 21 days following the injury, the right and left TA muscles 
were excised to determine if treatment of 17-AAG altered markers of regeneration.   Following 
dissection, TA muscles were weighed and immediately frozen in liquid nitrogen and stored at -
80°C for Western blots analysis of Hsp70, TNF-α, myogenin and GAPDH.  A subset of TA 
 muscles from days 7, 14 and 21 were mounted in a medium (O.C.T., Merck, UK), frozen rapidly 
in 2-methylbutane cooled in liquid nitrogen, and sectioned for histological analysis to determine 
the CSA of the regenerating fibers.  For both groups, the contralateral (right) TA musc
as an uninjured baseline, but also to determine if 17
state.  In the event that uninjured muscles did not differ across time, they were combined into 
their respective groups and listed as “uninjured 
 To assess if 17-AAG attenuated strength deficits following the BaCl
vivo isometric torque produced by the left anterior crural muscles (TA, extensor digitorum 
longus and extensor hallucis muscles) was measured immediately prior to the injury (day 0), and 
7, 14 or 21 days into recovery.  Due to significant swelling and edema, torque was not assessed 
1.5 and 3.5 days post-injury.  See Figure 9 for the timeline of the experimental design.
Figure 9.  Timeline (in days) of the experimental design.  Treatment was either an 
intraperitoneal injection (i.p.) of 40 mg/kg of 17
Tibialis anterior (TA) muscles were removed from anesthetized mice and stored fo
analysis or histology.  On day 0 (immediately pre
torque was assessed. 
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-AAG affected the muscle in the unstressed 
control” or “uninjured 17-AAG”.
2-induced injury, 
-AAG suspended in DMSO or a vehicle, DMSO.  
-injury) and 7, 14 or 21 days post
les served 
 
in 
 
 
r Western blot 
-injury in vivo 
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Experimental methodology 
 Barium chloride (BaCl2)-induced skeletal muscle injury 
Immediately after recording peak isometric torque, 50 µl of a 1.2% BaCl2 solution (diluted in 
sterile saline) was injected into the left TA muscles of the anesthetized mice using a 28 guage 
needle as previously described (43).  Briefly, the needle was inserted at the origin of the TA, 
extended past the mid-belly of the muscle to a region just superior to the distal tendon.  Next, the 
diluted BaCl2 solution was continuously injected into the TA muscle as the syringe was slowly 
removed.  
 Protein extraction, protein quantification and Western blotting 
A portion of TA muscles (10-15 mg/muscle) were homogenized in ice-cold RIPA lysis and 
extraction buffer (Thermo Scientific, Rockford, IL) supplemented with a protease inhibitor 
cocktail (Thermo Scientific, Rockford, IL).  Muscle homogenates were centrifuged at 10,000 g 
for 15 min at 4°C and protein content of the soluble portion (i.e., supernatant) was quantified 
using the bicinchoninic acid (BCA) assay (Thermo Scientific, Rockford, IL).  A portion of the 
muscle homogenate was then diluted in a loading buffer and boiled for 4 min.  Equal amounts of 
protein (30 µg) were loaded onto a 12% SDS polyacrylamide gel and separated according to 
molecular weight (100 V for 80 min).  The protein was then transferred to a nitrocellulose 
membrane using a trans-blot turbo transfer system at a constant 1.3 A, up to 25 V for 7 min (Bio-
Rad Laboratories, Hercules, CA) and blocked for 1 h at room temperature in 5% nonfat dried 
milk (w/v) in tris‐buffered saline with 0.1% Tween‐20 (TBS‐T) on an orbital shaker.  Following 
the block, the membranes were probed with Hsp70 (HSPA1A, 1:6000; R&D Systems, 
Minneapolis, MN), TNF-α (52B83, 1:1000; Santa Cruz Biotechnology, Santa Cruz, CA),  
myogenin (F5D, 1:500; Santa Cruz Biotechnology, Santa Cruz, CA) and GAPDH (GA1R, 
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1:7500; Thermo Scientific, Rockford, IL) primary antibodies for 2 h at room temperature on an 
orbital shaker.  Following incubation in the primary antibodies, membranes were washed with 
TBS‐T (3 × 15 min) and then probed with the appropriate secondary antibody (goat anti-rabbit 
IgG, 1:15000; Sigma-Aldrich, St. Louis, MO or donkey anti-mouse IgG, 1:15000; Thermo 
Scientific, Rockford, IL) for 1 h at room temperature with shaking and washed as previously 
stated.  Membranes were treated with an enhanced chemilumescent solution (Thermo Scientific, 
Rockford, IL) prior to detection using a BioRad ChemiDoc imaging station (Bio-Rad 
Laboratories, Hercules, CA) and analyzed by densitometry using QuantityOne software (Bio-
Rad Laboratories, Hercules, CA).   
 Histology 
Transverse, serial sections at 10 µm were cut through the mid-belly of the TA muscles using a 
cryostat (Leica CM1850, Leica, Germany).  Sections were then processed for hematoxylin and 
eosin staining, dehydrated, mounted, and visualized at 10X with a VanGuard light microscope 
(VEE GEE Scientific, Kirkland, WA) as previously described (41-43).  Regenerating fibers were 
identified by the presence of centrally positioned nuclei.  Cross-sectional areas (CSA) of 
approximately 200 regenerated fibers per muscle were calculated using ImageJ software 
(National Institutes of Health, Bethesda, MD). 
 In vivo analysis of muscular torque 
Contractile function (i.e., torque–frequency relationship) of the left anterior crural muscles was 
measured in vivo immediately before (day 0), and 7, 14 or 21 days after injury induction as 
previously described (7, 8, 35).  Briefly, mice were anesthetized with isoflurane (1.5% isoflurane 
and 400 mL O2 per min) and placed on a temperature controlled platform to maintain core body 
temperature between 35 and 37°C.  The left knee was clamped and the left foot was secured to 
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an aluminum “shoe” that is attached to the shaft of an Aurora Scientific 300B servomotor 
(Aurora Scientific, ON, Canada).  Sterilized platinum needle electrodes were inserted through 
the skin for stimulation of the left common peroneal nerve.  Stimulation voltage and needle 
electrode placement were optimized with 5-15 isometric contractions (200 ms train of 0.1 ms 
pulses at 300 Hz).  Following optimization, contractile function of the anterior crural muscles 
was assessed by measuring isometric torque as a function of stimulation frequency (20-300 Hz), 
with peak isometric torque recorded at 300 Hz. 
Statistical Analysis 
An independent t-test or factorial ANOVA (treatment by time) was used for comparisons before 
or across the study, respectively.  A Bonferroni’s post hoc test was performed in the event of a 
significant ANOVA.  An α-level of ≤0.05 was used for all analyses.  Values are presented in 
mean±SEM.  All statistical testing was performed using SigmaPlot version 11.0 (Systat 
Software, San Jose, CA). 
 
Results 
Mouse body weights (BW) and tibialis anterior (TA) wet weights 
Mouse body weights did not differ between control and 17-AAG groups before or after the 
injury.  However, as a result of aging, body weights were 8-12% greater at day 21 relative to the 
pre-injury, and 1 and 3 day post-injury body weights (p<0.01) (Table 1). 
 Uninjured TA muscle wet weights were not different between groups or across time.  
Injured TA muscle wet weights also did not differ between control and 17-AAG groups.  Among 
the groups, the injury caused significant edema and increased muscle wet weights 20% 1.5 day 
post-injection (p<0.001).  By day 3.5, edema was still present, but large amounts of the muscle 
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fascicles were disorganized which reduced muscle weights comparable to that of the uninjured 
muscle.  Seven days post-injury, swelling was reduced and muscle wet weights declined 34% 
from day 3.5 (p<0.001).  By days 14 and 21, muscle wet weights were greater than that of the 
uninjured muscle (p<0.01) (Table 1). 
 
Table 1.  Mouse body weights (BW) and tibialis anterior (TA) weights. 
 Control      17-AAG 
 0d 1d 3d 7d 14d 21d  0d 1d 3d 7d 14d 21d 
n 27 12 10 10 10 7  27 11 14 10 10 7 
BW 
(g) 
24.3±
0.3a 
23.4±
0.5a
 
24.4±
0.7a
 
24.6±
0.3a,b 
24.5±
0.6a,b 
26.8±
0.4b,c  
24.6±
0.3a 
23.6±
0.4a 
23.7±
0.4a 
24.8±
0.6a,b 
25.2±
0.5a,b 
26.0±
0.7b,c 
TA 
(mg) 
42.4±
0.6a 
50.6±
1.4b 
44.6±
1.7a 
35.1±
1.2c 
48.2±
1.9b,d 
58.8±
2.9e  
43.3±
0.7a 
51.9±
2.0b 
40.3±
1.3a 
33.1±
1.6c 
46.8±
1.2b,d 
55.1±
0.4e 
 
Values are means ±SEM.  Mouse body weights (BW) and tibialis anterior (TA) weights across 
the study.  Time points 1.5, 3.5, 7, 14 and 21 reflect days post-injury whereas 0 indicates 
uninjured or pre-injury data.  No differences were detected in mouse BW or TA weights between 
the control and 17-AAG groups at any time point.  Sample sizes (n) also reflect the number of 
mice used for torque assessments before (day 0) and 7, 14 or 21 days following the BaCl2-
induced injury.  Values with same letter are not significantly different from each other. 
 
Soluble protein and GAPDH Content 
Treatment with the vehicle or 17-AAG did not alter soluble protein content of the uninjured TA 
muscles.  Further, soluble protein content of the injured TA muscles did not differ between 
groups in the days following the injury.  However, the BaCl2 injection reduced soluble protein 
content 1.5 (40%) and 3.5 (22%) days post-injury (p<0.001).  By days 7, 14 and 21 soluble 
protein content was similar to the uninjured TA muscles (Figure 10 A). 
 No differences were observed in GAPDH content of the uninjured control and 17-AAG 
groups across the study.  The BaCl2 injection resulted in large reductions in GAPDH content 1.5 
(96%) and 3.5 (82%) days post-injury (p<0.001), which were similar between groups.  By day 7, 
there as a trend for GAPDH content to be reduced when compared to pre-injury levels, (22%, 
p=0.07).  In the following weeks, GAPDH content was similar to that of the uninjured muscle 
 (Figure 10 B).  Because GAPDH, a common n
following the injury, Hsp70, TNF
Figure 10.  (A) Soluble protein and 
and after the BaCl2-induced skeletal muscle injury.  Soluble protein content was determined 
using a bicinchoninic acid (BCA) assay while GAPDH was determined using Western blot 
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ormalizing protein, was significantly altered 
-α and myogenin were expressed as absolute values.
 
(B) GAPDH content of tibialis anterior (TA) muscle before 
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analysis.  Muscles were assessed at day 0 (uninjured) and 1.5, 3.5, 7, 14 or 21 days post-injury.  
No differences were observed in soluble protein or GAPDH content between control and 17-
AAG groups at any time point.  The dashed line indicates content of uninjured control muscle.  
Uninjured: n=19-21/group, Injured: n=4-6/group.  Values are mean±SEM. 
 
Hsp70 Content 
Treatment with 17-AAG increased Hsp70 content ~500% in the uninjured muscle (p<0.001).  
Following the injury, Hsp70 content in both groups was below that of the uninjured control 
muscle, but these levels were similar between the groups.  However, due to the significant 
increase in Hsp70 content in the uninjured 17-AAG group, the drop in Hsp70 at 1.5 days (90%, 
p<0.001) was more pronounced when compared to the vehicle treated group (41%, p=0.11).  At 
3.5 days post-injury, Hsp70 content remained similar between the groups, but was still depressed 
by 85% (p<0.001) in the 17-AAG treated muscle while Hsp70 content in the control group was 
back to pre-injury levels.  By day 7, Hsp70 content in the control muscle increased 150% above 
pre-injury content (p=0.17), which slowly returned to baseline by day 21.  Hsp70 content in the 
muscle treated with 17-AAG was back to its pre-injury level by day 7 and remained there or 
slightly above through day 21.  Furthermore, at these time points (i.e., 7, 14 and 21 days), Hsp70 
content was greater in the 17-AAG groups when compared to the injured controls (p<0.001) 
(Figure 11 A). 
TNF-α Content 
No differences were detected in TNF-α content in the uninjured control or 17-AAG groups over 
the duration of the study.  The injury resulted in large increases in TNF-α content at days 1.5 and 
3.5 (p<0.001), which returned to pre-injury levels by day 7 and remained down through day 21.  
Specifically, levels of TNF-α in the injured control muscle were elevated 864 and 404%, and 893 
and 603% in the 17-AAG groups at 1.5 and 3.5 days post-injury, respectively.  By day 7, TNF-α 
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content in the control group was elevated 68% while TNF-α content remained 242% above its 
pre-injury levels in the 17-AAG group.  By days 14 and 21, TNF-α content was near or slightly 
above baseline levels.  Although no treatment by time interaction was observed (p=0.35), a 
significant treatment effect was found (p=0.045).  That is, TNF-α content was higher following 
the injury in the muscle treated with 17-AAG when compared to the vehicle treated muscle 
(Figure 11 B). 
 
Myogenin Content 
No differences were observed in myogenin content of the uninjured control and 17-AAG groups 
across the study.  As with TNF-α content, the injury resulted in a large increase in myogenin 
content at days 1.5 (~545%) and 3.5 (~415%) (p<0.001), which did not differ between the 
control and 17-AAG groups.  By day 7, myogenin content in the control group returned to pre-
injury levels while myogenin content in the 17-AAG group remained elevated by 360% 
(p<0.001) and was significantly greater than control content (p<0.001).  By days 14 and 21, 
myogenin content did not differ from baseline or between groups (Figure 11 C).  The results of a 
linear regression revealed that there was a positive relationship between TNF-α and myogenin 
content across the study (R2=0.71, p<0.001) (Figure 11 D). 
 Figure 11.  (A) Hsp70, (B) TNF-
muscle before and after BaCl2-induced skeletal muscle injury.  Protein
using Western blot analysis.  Muscles were assessed at day 0 (uninjured) and 1.5, 3.5, 7, 14 or 
21 days post-injury.  The dashed line indicates protein content of uninjured control muscle.  
Regression analysis of TNF-α and myoge
muscle injury (R2=0.71, p<0.001).  *Significantly different from control muscle at that given 
time point (p≤0.05).  **Significantly different from control muscle following the injury (p
Uninjured: n=17-19/group, Injured: n=4
 
 
63 
 
α and (C) myogenin content of the of tibialis anterior (TA) 
 content was determined 
nin content before and after the BaCl2-
-6/group.  Values are mean±SEM. 
 
(D) 
induced skeletal 
≤0.05).  
 Histology 
No differences in CSA were detected between groups or across time in the uninjured muscles.  
As the inflammatory response abated, small regenerating fibers were observed that matured in 
the weeks following the injury.  No differences in regenerating fiber 
the control and 17-AAG groups.  Regenerating fiber CSA was 47% smaller than the uninjured 
fibers 7 days post-injury (p<0.001).  By day 14, the regenerating fibers increased in diameter, but 
were still decreased by 25% compared to 
injury induction, the CSA of the regenerating fibers was similar to the uninjured fibers (Figure 
12 A and B). 
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CSA were detected between 
the uninjured fibers (p<0.001).  Twenty
 
 
-one days after 
 Figure 12.  (A) Histological and 
TA muscle fibers.  Uninjured data (day 0) was obtained from the right TA muscles while 
regenerating fibers, those with centralized nuclei, were assessed from the injured left TA muscles 
7, 14 or 21 days post-injury.  No differences were detected between control and 17
at any time point.  Uninjured: n=10
 
In vivo peak isometric torque 
The initial treatment of 17-AAG had no effect on a
before the BaCl2-induced injury.  In parallel, recovery of absolute and normalized peak isometric 
torque was also similar between the control and 17
isometric torque was depressed 76% and 27% at days 7 and 14 (p<0.001), but not different than 
pre-injury torque by day 21.  Normalized peak isometric torque followed a similar progression 
through day 14; however, remained 13% down 21 days post
B), likely due to the increase in body weight observed at this time point. 
Figure 13.  (A) Absolute and (B)
muscle before (day 0) and 7, 14 or 21 days post
the control and 17-AAG groups before or after the BaCl
Table 1.  Values are mean±SEM.
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(B) graphical depiction of the cross-sectional area (CSA) of the 
-11/group, Injured: n=3-4/group.  Values are mean±SEM.
bsolute or normalized peak isometric torque 
-AAG groups.  In general, absolute peak 
-injury (p<0.001) (Figure 13 
 
 normalized in vivo torque produced by mouse anterior crural
-injury.  No differences were observed between 
2 injection.  Sample sizes (n) are listed in 
 
-AAG groups 
 
A and 
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Discussion 
Recovery from injury is dependent on the muscle’s ability to regenerate, a highly coordinated 
process involving inflammation and myogenesis (52, 53),  both of which are controlled by 
intrinsic and extrinsic signaling proteins.  Of particular interest is TNF-α, a cytokine central to 
both the inflammatory and myogenic processes, and therefore a key regulator of skeletal muscle 
regeneration (53).  By up-regulating Hsp70 content, a stress sensor involved in inflammation, we 
were able to further increase TNF-α content in injured muscle.  Together, induction of Hsp70 
and thus TNF-α resulted in a sustained increase in myogenin content, a marker of myoblast 
differentiation.  However, these changes did not enhance regenerating fiber CSA or in vivo 
maximal isometric torque production.  These findings demonstrate that Hsp70 regulates TNF-α 
content, which in turn mediates myogenic signaling, but not regeneration or functional recovery 
following BaCl2-induced skeletal muscle injury in healthy young mice. 
 Several pharmaceutical agents have been used to increase Hsp70 content in skeletal 
muscle, one of which is the Hsp90 inhibitor 17-AAG (26, 34).  Others that have used similar 
dosing strategies of 17-AAG have reported four-fold increases in Hsp70 content (26) which is 
comparable to the five-fold increase we observed.  Furthermore, they reported 4 weeks of 17-
AAG treatment in uninjured muscle did not result in any significant changes in other heat shock 
proteins (e.g., Hsp73 and Hsp25), muscle mass, CSA, isometric force production, or twitch 
characteristics (26).  To that end, we also report treatment of 17-AAG does not affect muscle 
mass, CSA or maximal isometric torque, in addition to mouse body weight, soluble protein 
content or GAPDH, TNF-α or myogenin content in uninjured muscle.  These observations, in 
particular that TNF-α and myogenin are not altered by 17-AAG treatment in the unstressed state, 
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suggest that the changes due to 17-AAG treatment in the damaged muscle were dependent on the 
injury. 
 Chemical- and toxin-induced injuries (e.g. BaCl2, cardiotoxin, notexin) result in myofiber 
disruption (12, 43, 57), mass necrosis (12, 43, 57) and loss of function (9).  Following the 
intramuscular injection of BaCl2, Hsp70 content in the control group was reduced below baseline 
levels and slowly increased until day 7.  This increase is delayed when compared to other types 
of injury.  For example, Hsp70 content increases in the hours to days after eccentric contraction-
induced skeletal muscle injury (25, 51).  However, our laboratory has noted significant 
differences between these injury models.  Specifically, in the days following a bout of eccentric 
contractions soluble protein and GAPDH content remain unchanged (7) while only 5-10% of the 
myofibers show signs of histological degeneration (14, 35), which is in stark contrast to the 
dramatic histological perturbations and reductions in soluble protein and GAPDH content that 
pursue a single intramuscular injection of BaCl2.  Torque deficits are also more pronounced 
following BaCl2-induced injury when compared to that of eccentric exercise.  We have shown 
that a single bout of eccentric contractions can reduce maximal isometric torque up to ~55% 
which is, in part, mediated through disruptions to key excitation-contraction coupling proteins (7, 
13), whereas BaCl2 reduces torque by ~80% due to the frank loss of nearly the entire muscle.  
Therefore, the finding that Hsp70 content did not significantly increase in the injured control 
muscle is a reflection of both the nature and severity of the BaCl2-induced injury.  We propose 
that in the days following the injury, Hsp70 content, including any newly synthesized Hsp70, 
was either degraded or lost from the myofiber.  Although the latter has not been well 
documented following trauma-induced skeletal muscle injury, it seems entirely plausible Hsp70 
could translocate into circulation like other muscle proteins (e.g., creatine kinase, lactate 
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dehydrogenase) via disruptions in the T-tubule and plasma membranes.  Moreover, loss of 
skeletal muscle proteins is a common consequence of eccentric exercise (6, 35, 49) and given 
that BaCl2 results in greater damage, it is likely to occur following this type of injury, and to a 
greater extent. 
 Release of Hsp70 into the extracellular environment has been reported following physical 
exercise (20, 55) and injury to heart (17, 18), liver (27) and skin (28) tissue.  Extracellular Hsp70 
(eHsp70) is thought to modulate the innate immune response by facilitating pro-inflammatory 
processes through the recruitment of immune cells (1, 2, 21, 46).  Previous studies have 
demonstrated eHsp70 can interact with various surface receptors expressed on specific immune 
cells, such as neutrophils (23, 40), macrophages and peripheral blood monocytes (3, 4, 28) 
thereby activating them.  Until recently, little evidence was available to support this notion in 
skeletal muscle following injury.  Using an Hsp70 knockout mouse model, Senf et al. (46) 
reported that acute inflammation was delayed in cardiotoxin injured muscle, which was followed 
at later time points by sustained inflammation and muscle fiber necrosis, fibrosis and reduced 
CSA of regenerating myofibers.  By reintroducing Hsp70 into the muscle prior to the injury via 
Hsp70 intracellular expression plasmids, they were able to completely restore early immune cell 
infiltration and prevent any changes that would have followed due to the ablation of Hsp70.  
Interestingly, they also found that TNF-α expression was significantly lower in the Hsp70 
knockout muscle 1 day post-injury when compared to injured controls, and as with the 
inflammatory response, TNF-α expression was restored when recombinant Hsp70 was injected 
into the muscle at the time of the injury.  In support of this, antigen presenting cells have been 
shown to significantly increase the release of TNF-α as early as 2-4 hours after exposure to 
exogenous eHsp70 (4, 5).  TNF-α appears to be critical to skeletal muscle regeneration, as we 
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and others report increased expression of TNF-α (10, 56, 58) and its receptors (58) 1-3 days into 
recovery, while TNF-α neutralization (56) and TNF-α receptor ablation (9, 56) significantly 
exacerbated long-term strength deficits following trauma-induced injury.  Using 17-AAG to 
induce Hsp70 expression, we found that these treated mice had significantly higher levels of 
TNF-α when compared to the vehicle-treated controls.  Furthermore, this effect was only 
observed in injured muscle, most evident 1.5 to 7 days following the BaCl2 injection.  Knowing 
this type of injury results in severe damage and that eHsp70 can initiate the inflammatory 
response.  We propose that TNF-α was higher in the 17-AAG groups due to the release of a 
larger amount of intracellular Hsp70 in the days following the injury, subsequently increasing 
eHsp70 content and thereby enhancing immune cell recruitment and the release of TNF-α from 
antigen presenting cells. 
 In skeletal muscle, TNF-α can be released by infiltrating immune cells or expressed by 
the myofiber following injury (11, 29, 58).  TNF-α activates NF-κB signaling which further 
increases TNF-α expression and promotes the inflammatory response (22).  Thus, TNF-α is a 
critical modulator of acute inflammation which is necessary for normal regeneration after injury 
because immune cells phagocytize damaged cellular debris and secrete growth factors that 
promote myogenesis.  In addition to its role as an inflammatory mediator, TNF-α can also 
stimulate myogenesis through p38 MAPK (9, 10, 59).  Data from Chen et al. (9) demonstrated 
multiple p38 MAPK-mediated steps in myoblast differentiation are TNF-α signaling dependent, 
with physiological levels of TNF-α stimulating differentiation through MEF-2 phosphorylation, 
induction of myogenin and the Cdk inhibitor p21, and suppression of cyclin D1.  In the present 
study, myogenin content was ~4-6 fold above baseline levels for up to 3.5 day post-injury in both 
the control and 17-AAG groups.  Intriguingly, myogenin content remained significantly 
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evaluated until day 7 in the 17-AAG group, even though both groups were injured to the same 
degree as evident by regeneration fiber CSA and isometric torque production.  We propose that 
as a result of injury, eHsp70 increased TNF-α expression thereby activating p38 MAPK, 
subsequently increasing myogenin expression.  In support of this, we found that TNF-α and 
myogenin content were directly related.  In that, TNF-α and myogenin were barely detectable in 
the uninjured muscle, but increased in parallel in the days following the injury.  Furthermore, 
TNF-α expression has been shown to positively correlated with the regenerative activity of 
injured muscle (29), while ablation of the TNF-α receptors is known to suppress myogenin 
expression following cardiotoxin-induced injury (9). 
 Despite the fact that 17-AAG increased Hsp70, TNF-α and myogenin content, treatment 
did not result in any observable changes in recovery as assessed by regenerating fiber CSA and 
maximal isometric torque production.  In contrast, others have shown Hsp70 induction decreases 
muscle damage, improves morphological recovery (36) and attenuates strength deficits (26, 36) 
following eccentric contraction-induced injury.  For example, using the same drug, dosage and 
treatment, Kayani et al. (26) reported improved recovery of maximal tetanic force following a 
bout of eccentric contraction in aged mice.  It is possible that Hsp70 induction prior to eccentric 
injury is involved in refolding denatured proteins such as myosin heavy chain and actin, that 
otherwise would have been degraded in the absence of Hsp70, a concept that would not be valid 
after BaCl2-induced injury due the unpreventable necrosis and degradation that follows.  
Additionally, if the muscle’s ability to express Hsp70 and/or induce its expression is diminished 
following injury, as seen with aging (36, 54), Hsp70 content may be rate limiting.  Up-regulation 
of Hsp70 not only mediates this issue after eccentric contraction-induced injury in aged rodents 
(26, 36), but also has been shown to be advantageous in models of age- (36) and disuse- (15, 34, 
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45) skeletal muscle atrophy.  As with Hsp70, TNF- α and myogenin are also not likely to be rate 
limiting in injured but otherwise healthy young muscle and therefore, as we show, increasing 
their expression does not translate into improved skeletal muscle regeneration or recovery. 
 We report that up-regulation of Hsp70 by the pharmaceutical 17-AAG increased TNF-α 
content above that normally observed following BaCl2-induced injury.  Furthermore, changes in 
TNF-α were found to be directly correlated to that of myogenin, indicating TNF-α expression is 
associated with myoblast differentiation.  The elevated levels of Hsp70 and thus TNF-α were 
able to sustain the increase in myogenin content observed in the days following the injury.  
However, the increased content of these proteins was not followed by any significant changes in 
regenerating fiber CSA or in vivo maximal isometric torque production.  In conclusion, Hsp70 
induction in healthy young mice prior to BaCl2-induced skeletal muscle injury increases TNF-α 
and myogenin content but does not appear to alter skeletal muscle regeneration or attenuate 
functional deficits in the weeks following the insult. 
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APPENDICES 
 
Appendix A: IACUC Original Protocol and Amendments 
Georgia State University 
Institutional Animal Care and Use Committee 
RESEARCH PROTOCOL FOR ANIMAL CARE AND USE 
For Office Use Only 
Date Received:   
Protocol Number:   
Protocol Title:   
Principal Investigator:   
Veterinary Review Date:   
Revision Date:   
Final Approval Date:   
Protocol Number Replacing:   
Biosafety Approval Needed: Yes    No   Approval Date___________ Approval Number________ 
Radiation Safety Approval Needed: Yes    No  Approval Date_____ Approval Number________ 
 
  
Signature of Attending Veterinarian ________________________________________________________________ 
 
 
Signature of IACUC Chair ________________________________________________________________________ 
 
The Institutional Animal Care and use Committee (IACUC) is by law responsible for ensuring that the use of 
animals at Georgia State University is performed according to the highest standards and in an ethical manner. This 
responsibility is shared with university faculty, staff, and students. The use of animals at the university is a privilege, 
not a right. Maintaining this privilege requires compliance with the following regulations, policies, and guidelines: 
Animal Welfare Act Regulations 
Public Health Service Policy on Humane Care and Use of Laboratory Animals 
The Guide for the Care and Use of Laboratory Animals 
U.S. Government Principles for the Utilization and Care of Vertebrate Animals Used in Testing, Research, and 
Training 
The authority of the IACUC is derived from these laws and policies. The IACUC’s role in institutional self-
regulation ensures that animals are not subject to unnecessary pain and distress. Furthermore, by assuring 
compliance with these animal welfare laws and guidelines the IACUC also protects the investigator and the 
institution. The IACUC must review all aspects of the animal care and use program. The animal care and use 
program must include: 
 
A properly constituted and functioning IACUC 
Procedures for self-monitoring 
An adequate veterinary care program 
An occupational health and safety program 
A training program for personnel 
An environment, housing, and management program for animals 
Appropriately maintained facilities for housing and support 
 
Central to the IACUC’s mandated functions are (1) reviewing and approving animal use protocols submitted by 
investigators and (2) semi-annual program reviews and facility inspections. 
This form is intended to facilitate review of requests to use animals for specific research, instruction, or biological 
testing projects.  
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• This completed form must be reviewed and approved by the IACUC before the project or course is 
initiated and before animals can be procured. 
• After 3 years a new complete AUP must be submitted, approved and assigned a new number. 
• The number of animals used must be declared annually and their documentation is the responsibility of the 
Principal Investigator. 
 
The Georgia State University IACUC Policies and Procedures Manual can be found on line at:  GSU IACUC 
Policies and Procedures Manual  This document contains information on Completing the Protocol Form, Protocol 
Review and Approval, Required Training, The Occupational Health Program, Additional Considerations Pertaining 
to Protocols, and more. 
 
PLEASE COMPLETE A SEPARATE PROTOCOL FOR EACH DIFFERENT TYPE OF ANIMAL OR 
PROJECTS WITH DISTINCTLY DIFFERENT PURPOSES USING THE SAME TYPE OF ANIMAL (e.g. 
experimental protocol and breeding protocol).  
 
SECTION 1.  Basic Protocol Information 
 
1.1 PROTOCOL TITLE: Alcoholic myopathy and skeletal muscle regeneration 
1.2  DATE:  
1.3  PRINICPAL INVESTIGATOR: Jeffrey S. Otis, PhD 
1.4  DIVISION: College of Education: Dept. of Kinesiology and Health  
1.5  E-MAIL: jotis@gsu.edu 
 
1.6 General Animal Information 
 
1.6.1 Over a period of three (3) years I would like to use a total of  __440____   (number) animals. 
1.6.2 Common name: Mouse 
1.6.3 Scientific name: Mus musculus 
1.6.4 I would like to begin using these animals on (date): October 1, 2013 
1.6.5 I will obtain animals from (name of supplier): Harlan 
1.6.6 I will breed these animals:  
 Yes (If yes, justify in Section 14 “Animal Housing & Husbandry” below).  
Where will breeding stock be obtained? (Name of supplier):  
 No  
 
1.7 List All Funding for the Proposed Animal Work:   
GRANT TITLE  GRANTING AGENCY 
 
 GRANT # 
(1) Chronic alcohol-induced skeletal muscle myopathy: 
etiology and physiology  NIH/NIAAA   5K01AA17190  
(2) Departmental start-up funds 
    
     
1.7.1. If Funding for the Proposed Animal Work is from the following sources, please submit the 
required documents listed below.   
NIH funding - please attach the following:  
Project/Performance Site Location(s) 
Project Summary Abstract 
Project Narrative 
Research Plan Attachments: 
Specific Aims 
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Research Strategy 
Vertebrate animals (grants.nih.gov/grants/olaw/VASfactsheet_v12.pdf) 
 
NSF funding - please attach the following:  
Cover sheet 
Project Summary 
Results from prior NSF support 
Explanation of Revisions 
Project Description 
Research Plan 
 
1.8 Three Year Renewal 
If this is a 3 year renewal, please answer the following questions.  If not, please skip to section 1.10. 
 
1.8.1 What is the number of the protocol this is replacing?  
1.8.2  Do you presently have any live animals under this number?  
1.8.3  If yes, will these animals be transferred to your new protocol once it is approved?  
1.8.4  As this is a 3-year renewal, the IACUC requests that you provide a very brief description of the 
outcomes of the work conducted under the existing approval:  
 
1.9 Location of work on project 
 
1.9.1 Will any aspect of the study (course) or animal husbandry be conducted at another institution? If 
so, please name the institution: No 
1.9.2 If yes, please provide the PHS Assurance number of the institution where this work will occur:  
1.9.3 Has this proposal been approved by the IACUC of that institution?  
If yes, please attach a copy of the approved protocol and a copy of the dated and signed approval 
letter. 
 
1.10 Veterinary Care and Consultation: Principal Investigators may discuss the proposed project with the 
Attending Veterinarian before submission of the application to the IACUC. Procedures involving more 
than momentary or slight pain or distress (USDA Pain Category “D” or “E”) must be discussed with the 
Attending Veterinarian in the planning of the research project. All protocols and amendments will be sent 
to the Veterinarian for review of animal care issues after submission.  
 
1.11 Certification of Compliance:  I will comply with the procedures described in the NIH Guide for the 
Care and Use of Laboratory Animals, with PHS policy, the Animal Welfare Act, and the GSU 
IACUC Policies and Procedures Manual. I acknowledge responsibility for the procedures described 
and assure that the faculty, staff and students who perform these procedures are qualified (or will be 
adequately trained) to conduct them in a humane manner.  Failure to comply may result in sanctions 
by the IACUC including, but not limited to suspension of research activities. 
 
Signature of the Principal Investigator ___________________________________ 
Date ____________ 
 
SECTION 2.  Lay Project Summary and Overview 
 
2.1 Objective(s) (What are you doing?) 
Please provide a brief statement, in LAY TERMINOLOGY understandable by someone with a college 
education, with no acronyms or scientific jargon, outlining the objective of the procedures of this protocol. 
Begin with a broad statement concerning the overall problem (e.g., “Pancreatic cancer kills ~50,000 
Americans each year. We are addressing this problem by ….”). Include a statement of your experimental 
hypothesis or objectives. Please do not submit your grant proposal abstract for this section. Define all 
abbreviations the first time they are used and explain medical terms. You will be asked to provide a 
scientific summary of the project in a later section.  
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  The NIH has estimated that nearly 18 million Americans abuse alcohol.  Chronic alcohol ingestion may 
produce a variety of complications that include skeletal muscle wasting (termed alcoholic myopathy).  Our 
goal is to improve skeletal muscle function in chronic alcoholics (using well-established rodent models of 
chronic alcohol ingestion).  We and others have shown that chronic alcohol ingestion is associated with 
oxidant stress.  Importantly, we are able to reduce this alcohol-induced oxidant stress by providing alcohol-
fed animals the antioxidant glutathione (as S-adenosylmethionine, SAMe).  In parallel, we have shown that 
alcoholic muscle has a reduced ability to regenerate following injury – an effect we believe to be due, in 
part, to elevated oxidant stress. 
 
We are addressing these problems via nutritional intervention and SAMe supplementation.  As such, we 
hypothesize that alcoholic myopathy in both injured and uninjured skeletal muscle may be improved by 
glutathione restoration. 
 
 
2.2 Rationale and Significance (Why are you doing it?) 
Please provide a brief statement about how contributions from your proposed work might be relevant to 
human/animal wellbeing or the expansion of knowledge. This must be written in LAY TERMINOLOGY, 
understandable by someone with a college education, with no acronyms or scientific jargon. Please do not 
submit your grant proposal abstract for this section. Define all abbreviations the first time they are used 
and explain medical terms.  
 About 45-70% of chronic alcoholics, defined as those that drink in excess of 100 g of ethanol (EtOH) 
for more than 10 years, show significant damage to skeletal muscle, including muscle wasting, debilitating 
fatigue, and weakness. Chronic alcohol abusers may be more likely to suffer skeletal muscle injuries due in 
part to muscle atrophy and weakness, nerve damage, increased incidence of risky behaviors, and general 
misbalance.  However, no research exists on the capacity of alcoholic skeletal muscle to regenerate 
following injury.  
 
While there are several causes for these myopathies, we have focused on the powerful antioxidant 
glutathione and the potential effects of elevated oxidant stress.  Glutathione is the principle free radical 
scavenger (antioxidant) in skeletal muscle and is crucial for normal skeletal muscle function.  
Unfortunately, we and others have shown that the available pool of glutathione is drastically reduced in 
alcoholic muscle which may be responsible for the extent of alcohol-induced skeltal muscle wasting.  
Further, reduced glutathione levels may leave alcoholic muscle at a significant disadvantage to repair itself 
following muscle injury.  Accordingly, we hypothesize that restoring glutathione balance in alcoholic, 
injured muscle with antioxidant supplementation therapy will improve skeletal muscle health following 
injury. 
 
2.3 Justification for the Use of Animals 
Please justify why animals must be used instead of using methodology that does not require vertebrate 
animal use. Provide a brief statement justifying your use of animals in the proposed project. 
The skeletal muscle degenerative and regenerative response following injury requires complex multi-
organ communication, including metabolic, hematological, immunological, and pathophysiological 
involvement. Therefore, these effects of skeletal muscle injury and the consequent regenerative process can 
only be modeled in vivo. Similarly, the catabolic effects of alcohol and the anti-oxidant effects of 
glutathione replacement therapy (SAMe) must be modeled in vivo to account for appropriate drug 
metabolism.  
 
SECTION 3.  Overall Animal Use Category Information 
 
If the answer to any of the following questions is YES, please provide a brief explanation. 
3.1 Will any technique be performed which will involve prolonged physical restraint (> 30 minutes) other 
than routine caging and handling? No 
If yes, describe the type, method and the length of time the animal is restrained.  
3.2 Will any substance such as Complete Freund’s Adjuvant or other adjuvants be injected which could 
cause chronic inflammation and/or pain? No 
If yes, describe what will be used, volumes, and the schedule for the injections.  
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3.3 Will it be necessary for live animals to be removed from the animal facility? Yes 
3.4 Will this experiment involve stress, pain, or abnormal behavior in live animals, which cannot be 
alleviated with drugs because their use would interfere with the research goal? Yes 
 3.4.1 Will any adverse effects or overt signs of illness be expected? No 
3.5  Will animals be subjected to more than one major survival surgical procedure? No 
Major surgery penetrates and exposes a body cavity, produces substantial impairment of physical or 
physiologic function, or involves extensive tissue dissection or transection.  Please note that routine 
injections are not considered surgical procedures. Please refer to OLAW Position Statement 5) Multiple 
Surgical Procedures to determine whether it is appropriate to perform more than one major surgical 
procedure. 
3.6 Will food or fluid be restricted and/or regulated? No 
3.7 Will field investigations be employed? No 
If yes, please provide all the relevant permits.  
 
SECTION 4.  USDA Animal Use Category Classification  
 
USDA Classifications and Examples of Pain Categories: 
Classification B: Animals being bred, conditioned, or held for use in teaching, testing, experiments, research, or 
surgery, but not yet used for such purposes. 
Examples: 
• Breeding colonies - Includes parents and offspring.  
• Animals held under proper captive conditions or wild animals that are being observed.  
 
Classification C: Animals upon which teaching, research, experiments, or tests will be conducted involving no pain, 
distress, or use of pain-relieving drugs. 
Examples: 
• Procedures performed correctly by trained personnel such as the administration of 
electrolytes/fluids, administration of oral medication, blood collection from a common peripheral 
vein per standard veterinary practice or catheterization of same, standard radiography, parenteral 
injections of non-irritating substances.  
• Euthanasia performed in accordance with the recommendations of the most recent AVMA Panel 
on Euthanasia, utilizing procedures that produce rapid unconsciousness and subsequent humane 
death.  
• Manual restraint that is no longer than would be required for a simple exam; short period of chair 
restraint for an adapted nonhuman primate.  
 
Classification D: Animals upon which experiments, teaching, research, surgery, or tests will be conducted 
involving accompanying pain or distress or leading to illness to the animals and for which appropriate anesthetic, 
analgesic, or tranquilizing drugs will be used. 
Examples: 
• Surgical procedures conducted by trained personnel in accordance with standard veterinary 
practice such as biopsies, gonadectomy, exposure of blood vessels, chronic catheter implantation, 
laparotomy or laparoscopy.  
• Blood collection by more invasive routes such as intracardiac or periorbital collection from 
species without a true orbital sinus such as rats and guinea pigs.  
• Administration of drugs, chemicals, toxins, or organisms that would be expected to produce pain 
or distress but which will be alleviated by analgesics.  
 
Classification E: Animals upon which teaching, experiments, research, surgery, or tests will be conducted involving 
accompanying pain or distress or leading to illness to the animals and for which the use of appropriate anesthetic, 
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analgesic, or tranquilizing drugs will adversely affect the procedures, results, or interpretation of the teaching, 
research, experiments, surgery, or tests. 
Examples: 
• Procedures producing pain or distress unrelieved by analgesics such as toxicity studies, microbial 
virulence testing, radiation sickness, and research on stress, shock, or pain.  
• Surgical and postsurgical sequella from invasion of body cavities, orthopedic procedures, dentistry 
or other hard or soft tissue damage that produces unrelieved pain or distress.  
• Negative conditioning via electric shocks that would cause pain in humans.  
• Chairing of nonhuman primates not conditioned to the procedure for the time period used.  
 
4.1 Selection of Pain Category  
Please classify the project according to the level of perceived pain / stress / distress experienced by the 
animal(s). Animals must be claimed under the highest class involved at any point prior to euthanasia or 
release. Highest Pain Category within this protocol:     (enter B, C, D, or E) 
Class E 
4.2 Justification of Pain Category “E” 
If category E is selected, please provide a scientific justification for withholding pain and/or distress relief.  
We have previously shown that COX2 inhibition (via non-steroidal anti-inflammatory drug delivery) can 
reduce skeletal muscle cell proliferation (Otis et al., Exp Cell Res 2005, 310(2):417-425.). Thus, we 
hesitate to use analgesics following BaCl2-induced injury as it may impede skeletal muscle repair.   
 
In our experience with this model (Dekeyser and Otis, Reg Med Res 2013, in press), mice ambulate 
normally upon awakening from anesthesia and do not appear to be in pain post-procedure or during the 28 
day recovery process (i.e., no signs of failure to groom or roughed coat, decreased appetite, 
vocalization).  Further, we have monitored body weight and show no significant difference between groups 
– either due to diet or due to injury. 
 
4.3 Monitoring of Animal Pain and Comfort Levels 
 
4.3.1 Who will be responsible for monitoring the animals for pain and/or distress during the 
experimental procedure(s)? 
Jeffrey S. Otis, DAR staff including veterinarians 
4.3.2 How will the comfort level of the animals be determined?  
Pain or distress will be visually monitored.  Potential signs of distress due to injury may include 
increased vocalization or favoring the injured hindlimb.  However, we have not seen any of 
these signs in the animals.  Animals will be monitored 2-3 hours following BaCl2 injection and 
then 2 to 3 times per work week by the PI. 
4.3.3 In the event that an animal needs to be euthanized or removed from the experiment, please list the 
criteria for the decision. Describe the humane endpoint criteria to be applied and the frequency of 
monitoring for these humane endpoints. 
Should an animal require euthanasia because of significant stress, appropriate Georgia State 
University guidelines will be followed as identified in the GSU IACUC policies and procedures 
guideline located on the IACUC website (http://www.gsu.edu/research/iacuc.html).   
 
Accordingly, euthanasia will be performed via CO2 inhalation and confirmed by thoracotomy 
and diaphragm removal. 
 
4.3.4 Who will determine this action? 
Jeffrey S. Otis and/or GSU veterinary staff 
4.3.5 Will animal models with tumors be utilized? No 
If yes, please review the following: 
http://www.gsu.edu/images/vp_research/GSU_IACUC_Policy_on_Mouse_Tumor_Burden.doc 
I will adhere to the standards specified in this policy. 
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 Yes   
  No (If No, scientifically justify below):  
 
 
Section 5.  Alternatives and Non-duplication 
 
5.1 Explanation for the Consideration of Alternatives for Category “D” or “E” Animal Use.  
Federal Regulations (The Public Health Service Policy and the Animal Welfare Act) and University Policy 
require assurance that this project does not unnecessarily duplicate research projects/courses performed at 
this or other institutions, and that the use of alternatives to live animal models and alternative procedures 
that may cause more than momentary or slight pain/distress (Class “D” and “E” procedures) to animals 
have been considered. The information in this section should include adequate information for the IACUC 
to assess that a reasonable and good faith effort was made to determine the availability of alternative 
models or methods.  
 
The following is a guide for answering 5.1.1 and beyond. 
Your literature search is done as part of the OLAW requirement to address the “3Rs” (Refinement, 
Reduction, and Replacement) issues.  For example:  
 
* Refinement of procedures to eliminate or minimize pain or distress, the use of remote telemetry to 
decrease the distress of restraint; the use of humane endpoints. 
 
Other examples of refinement are: ways to enhance the well-being of animals and the use of analgesics to 
decrease pain or anesthetics to decrease distress. These should be addressed only in Section 10.  
 
For the literature searches 
 
Ask "Am I using the least painful technique(s)?” 
 - Search terms: Your species + animal/experimental model/technique + scientific keywords 
 
* Replacement of live animals with non-animal procedures or a less sentient species. Examples include the 
use of non-animal models such as in-vitro work, cell culture, tissues culture, computer models or 
simulations.  
 
Ask "Do I need to use animals?": 
 - Search terms: Your experimental model + simulation + in vitro +scientific keywords  
 
Ask "Am I using the lowest species possible?": 
 - Search terms: Your species + all applicable lower species (For example if using mice, specifically use 
"invertebrate", "fish" and "frog" in your search terms) + your animal/experimental model + scientific 
keywords 
 
Note: There are NO search terms that will direct the searcher to all examples of replacement or 
refinement. The onus is on the researcher to read and evaluate the literature.  
 
*Reduction in the number of animals used in the study. (This only needs to be addressed in Section 9.2 
of the protocol not here).  Examples include the use of shared control groups; preliminary screening in 
non-animal systems; innovative statistical packages.  
 
 
The selection of databases depends on the work performed and the species used in the protocol. Samples 
of databases available through the Georgia State University Library www.library.gsu.edu/database web 
pages 
 
· PubMed·   Web of Knowledge · Biological Abstracts·   Web of Science    PsychINFO    AltWeb    NLM 
Gateway     AVAR     Galileo     AGRICOLA 
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 OVID (allows a search of multiple databases including Agricola, BIOSIS, CAB Abstracts, Medline, 
Zoological Record, etc.)  
 
Please visit the Animal Welfare Information Center (AWIC) Literature Searching and Databases page 
(http://awic.nal.usda.gov/nal_display/index.php?tax_level=1&info_center=3&tax_ subject=184) for a list 
of databases that can be used to search for alternatives. The AWIC site also recommends using the 
Literature Search Worksheet (http://www.nal.usda.gov/awic/alternatives/searches/altwksht.pdf) to assist in 
performing a successful alternatives database search. The worksheet helps to identify relevant searchable 
terms and concepts. 
 
5.1.1 Literature search for alternatives to painful procedures 
If you chose category “D” or “E” above, please do literature searches using the broadest database 
for your area of study, and provide a brief summary of the results obtained to verify that you 
investigated the use of alternatives to painful or distressful procedures. If you have not selected 
either category D or E, skip to section 6.2. 
 Alcohol studies: 
The vast majority of research on the toxic effects of alcohol on skeletal muscle have been 
 performed in vivo (for review, see: Preedy et al., J Muscle Res Cell Motili. 24(1): 55-63,  2003.  
While culturing muscle cells may uncover novel signaling mechanims, the complex  metabolic 
response secondary to alcohol metabolism is best investigated using whole  animals models. 
 
Muscle injury studies: 
Muscle repair can be modeled in vitro by looking at the ordered sequence of events  during 
myogenesis (i.e., myoblast proliferation, differentiation, fusion, and myotube  growth) (for review see: 
Abmayr and Pavlath, Development, 139(4): 641-656, 2012).   However, effective muscle repair requires 
input and signaling from multiple cell types  such as infiltrating immune cells – events that are best 
modeled in vivo. 
 
5.1.1.1 Name of the databases used:   Pubmed, ALTBIB 
Date the databases search(es)  were done:   August 19, 2013 
Did the search cover the entire date range of the databases with no restriction on dates? 
 Yes   
  No (If No, provide dates covered by the search(es) below) 
Dates covered by the databases search(es):   
 
5.1.1.2 Search keyword(s) used: include number of hits for combinations of terms. You must use 
‘alternative’ and ‘animal welfare’ in the search combinations for invasive or painful 
procedures (See above for 3R criteria.) 
 alcoholic myopathy, skeletal muscle regeneration, skeletal muscle injury, animal testing 
 alternatives, animal welfare, and alternative 
(1) Alcoholic myopathy + animal welfare = 0 
(2) Alcoholic myopathy + alternative = 0 
(3) Skeletal muscle regeneration + animal welfare = 0 
(4) Skeletal muscle regeneration + alternative = 10 
(5) Skeletal muscle injury + animal welfare = 0 
(6) Skeletal muscle injury + alternative = 5 
 
5.1.1.3 Summarize the information found in the hits below.  (Note: this should be a general summary. 
You do not need to go into the details of each hit but rather summarize hits by relevant groups)  
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Searches 4 and 6 from above returned similar studies.  These studies describe 
experiments performed in vivo using mouse models, or in primary cells isolated from 
rodent tissues.  The in vivo studies track regeneration over time (as we intend to do in the 
protocol), while the in vitro studies use a surrogate model of muscle regeneration.  As we 
have stated in 5.1.1, using an in vitro model system does not accurately represent 
complications that arise from chronic alcohol ingestion.  
 
5.1.2 Explain what alternatives exist in place of using animals for this protocol and provide a 
justification if these cannot be used.  
 Alternatives do not include less sentient species and are limited to in vitro systems.   These 
can not be used for reasons described in 5.1.1. 
 
5.1.3 Other Sources of Information on Alternatives to Painful Procedures 
 
5.1.3.1 Consultation with Experts: (Names, credentials, and dates):   Mike Huerkamp, DVM  
 2005-2013.  I sat on the Emory IACUC for 4 years and had frequent conversations with Mike 
 (Director of DAR) and other IACUC members about animal welfare. 
5.1.3.2 Scientific Meetings: Specify:   NA 
 
Note: A careful literature search is usually the best way to determine whether a proposed study is unnecessarily 
duplicative of previous work. However, it is ok to repeat a published experiment to make sure that it works in a 
different lab. This reason just needs to be stated as the justification.  
 
5.2 Consideration of non-duplication 
 
5.2.1 Please provide a written assurance that the proposed work is not unnecessarily duplicative.  All 
experiments described in this protocol are novel, and do not duplicate previously published work. 
 
Section 6.  Method(s) of Euthanasia 
 
6.1 Describe in detail the method of euthanasia (if any) you will use. If the method involves the use of 
pharmaceuticals, please specify agent, dose, and route of administration.  Please note that methods of 
euthanasia must be in accordance with the most current American Veterinary Medical Association Panel on 
Euthanasia.  References must be cited to justify deviations from this document, or to justify use of cervical 
dislocation or decapitation without anesthesia.   
Should an animal require euthanasia because of significant stress or has completed their 
 experimental time period, appropriate GSU guidelines will be followed.  Euthanasia will be 
 performed via CO2 inhalation followed by thoracotomy to confirm death.  
6.2 How will death be confirmed?   thoracotomy 
6.3 How will remains be disposed?   Animal carcasses will be disposed by putting them in the DAR 
designated freezers within the animal facility. 
6.4 If you chose Carbon Dioxide inhalation method above, please review the GSU IACUC Carbon Dioxide 
Euthanasia Policy.  
I will adhere to the standards specified in this policy. 
 Yes   
  No (If No, scientifically justify below):  
 
 
SECTION 7.  Justification for Animal Species Selection 
 
7.1  Animal characteristics 
7.1.1 Species Name: Mouse 
7.1.2 Strain (if any): C57Bl/6 
7.1.3 Age: ~8-10 wks 
7.1.4 Sex: Male 
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7.2 This species has been selected because (check all that apply) 
 Previous work in the biomedical literature validates the use of this species as an animal model for this 
disease or biological process. 
 This is the lowest sentient species that provides appropriate size, tissue or anatomy of the proposed work. 
 There is a large body of existing data that would need to be repeated if another species was used instead. 
 Available reagents or research tools necessary for this research are unique to this species. 
 Characteristics of this species make it uniquely suited for the proposed research. Explain:  
 Other (Explain):  
 
SECTION 8.  Animal Use Narrative 
 
8.1 Please describe in narrative form all experimental or instructional procedures to be performed on 
the animals. Please note that it is not necessary to provide the details already provided elsewhere in the 
protocol (e.g. procedure descriptions, volumes of blood collected, dosages, routes of administration, use of 
aseptic procedures, etc.). However, it is important that one is able to ascertain what procedure or set of 
procedures is conducted on each group of animals. Include the time frames and intervals between 
procedures and describe the procedures in the order they will be performed. 
Alcohol (EtOH) in drinking water 
Male, adult BALB/c mice will receive EtOH in drinking water for 14-18 weeks (depending 
 on group) and be compared to mice without EtOH in the drinking water. EtOH will be  added to 
the animals’ drinking water at an initial concentration of 5% and then gradually  increased by 5% every 4-5 
days until a final concentration of 20% (weight:volume) in the  drinking water is achieved. The 
animals are then continued on this regimen for 10-14  weeks and have ad lib access to solid rodent chow. 
Subgroups of control or alcohol-fed  animals will be supplemented with the glutathione precursor, 
S-adenosyl methionine  (SAMe, in drinking water).  
 
Glutathione replacement therapy using S-adenosyl methionine (SAMe) 
Injured or noninjured, control or EtOH-fed mice will be provided SAMe in the drinking water 
(0.4% w/v, Nutramax Labs).  SAMe-supplemented animals in the injury groups will begin 
glutathione replacement therapy one week prior to skeletal muscle injury. Thus, animals may 
receive SAMe for 9 days to 3 weeks.  Non-injured animals will be matched acordingly.  
 
Drug is pulverized, dissolved in control water or water + 20% EtOH, passed through 100 um 
filters, and poured into water bottles. During the work week (Mon-Fri), drug-treated water will be 
replaced every two days. Volumes will be sufficient to drug-treat animals over the weekend (Fri-
Mon). Static racks of drug-treated mice are noted with appropriate "SPECIAL WATER" signage. 
Discussions with our colleagues at Emory University (Viranuj Sueblingvong, David Guidot) 
suggest that the animals tolerate SAMe with ease and hydrate normally.  
 
Barium chloride-induced muscle degeneration 
Once mice have been on 20% alcohol water for 10 weeks, they will be anesthetized by isoflurane 
(2l O2/min).  Intramuscular injections of barium chloride (1.2% BaCl2 in sterile PBS, 50 µl final 
volume) will be injected into mouse tibialis anterior (TA) muscles. Uninjured, contralateral TA 
muscles serve as controls which greatly reduces are animal numbers. Briefly, the anterior shank of 
sedated animals will be shaved and the TA muscle will be identified via palpatation.  Next, a 27 G 
needle is inserted from the origin of the TA muscle and continued to the midbelly. The syringe is 
slowly removed as the contents are dispersed into the muscle tissue.  We have signficant 
experience with this model and histological examination of the anterior leg muscles confirm TA 
injury with no injury to deeper skeletal muscles such as the extensor digitorum longus (EDL). TA 
muscles will be collected 2, 7, 14, or 28 days post-BaCl2 injection (n=20/time) and assessed for 
markers of degeneration and regeneration (inflammatory response, cross sectional area, fibrosis) 
or processed for protein and gene expression analyses (CNTF, IL-6, IGF, anti-oxidants such as 
superoxide dismutase 1-3 and catalase). 
 
Mice undergoing BaCl2 injections recover from anesthesia on heated pads and are 
 monitored for 2-3 hours immediately post-injury and then daily (Monday-Friday) to identify 
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 any signs of stress. Should an animal require euthanasia because of significant stress, 
 appropriate GSU guidelines will be followed.  Euthanasia will be performed via CO2 
 inhalation followed by thoracotomy. 
 
BrdU administration 
Subgroups of mice (n=10/group) will receive 2 BrdU injections (0.3 ml of 100 ug/g separated by 8 
hrs, delivered i.p.) on the day of muscle injury in order to label replicating cells. Thereafter, BrdU 
(0.8 mg/ml drinking water) will be added to the drinking water for up to 7 days after muscle 
injury. Lab personnel will be responsible for providing and changing the drinking water once the 
animals start on this special drinking water.  Muscles are collected post-mortem for histochemical 
analyses of BrdU incorporation. 
 
Voluntary Wheel Running 
Subsets of animals will be housed individually in modified rat cages that  contain standard 
running wheels (PetsMart) equipped with a CatEye bike monitor. Daily running  distances will be recorded 
daily for up to 28 total days, as previously described (see:  Waters et al., Voluntary running induces 
fiber type-specific angiogenesis in mouse  skeletal muscle. Am J Physiol Cell Physiol 287: C1342-48, 
2004.) In general, we  hypothesize that chronic alcohol abuse +/- injury will reduce voluntary activity 
that may be  partially improved following SAMe supplementation. 
 
Animal usage 
Our estimates of the number of mice required to complete the goals of this project are based on 
power analyses (significance accepted at p ≤ 0.05, one sided), our extensive experience with these 
models, and our expected productivity. Mice are continually purchased, acclimatized to the diet, 
and euthanized prior to tissue collection. In our vast experience and in the absence of a power 
analysis, designating 20 mice per group is a sufficient number to identify a statistical significance 
between treatments and to account for animal attrition (see Figure below that depicts 300 animals).   
 
 
 
In addition, we are requesting 140 mice to complete the Voluntary Wheel Running experiments.  
These animals will be grouped as:  
(1) control-fed, uninjured (n=20),  
(2) control-fed, injured (n=20),  
(3) control-fed, injured + SAMe (n=20), 
(4) alcohol-fed, uninjured (n=20) 
(5) alcohol-fed, uninjured + SAMe (n=20) 
(6) alcohol-fed, injured (n=20) 
(7) alcohol-fed, injured + SAMe (n=20) 
 
  In all, we are requesting 440 mice over the next 3 years. 
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SECTION 9.  Justification for the number of animals that will be used 
 
9.1 Group sizes are expected to represent the minimum number of animals that are needed to achieve the 
scientific or instructional objectives. Please indicate all the methods used to determine these numbers. 
 Statistical tools, such as power analysis, were employed to determine appropriate group sizes to ensure 
statistically valid outcomes. (Please retain print outs from calculations.) 
 Previous experience with this experimental paradigm indicates this is the minimum number of animals 
needed.   
 Consultation with a biostatistician  
 This is a pilot study used to determine feasibility before proceeding with larger, more tightly controlled 
experiments.  
 This is an instructional activity. This is the minimum number of animals needed based on class size and 
optimal student to instructor ratios.  
 Other (Explain):  
 
9.2 Using the specifics of your experimental plan demonstrate how the numbers of animals required to achieve 
your scientific objectives for this project were calculated. Include details of numbers of animals per group, 
control groups, treatment groups, pilot studies, and potential experimental failure.  Information may be 
provided in the form of a table or flow chart. Justify the number of animals required for each 
procedure/experiment described in Section 10 using power analysis, if possible. For help with power 
analyses see: http://www.psycho.uni-duesseldorf.de/aap/projects/gpower/  
Justify the number of animals requested.  
 Power analyses were originally calculated by senior PI several years ago.  We have been routinely using 
these group sizes as mouse tissue can not be used for multiple experiments (e.g., physiology, biochemistry, 
histology).  As such, we have successfully used these animal numbers  for the past 8 years and are 
confident that they are accurate and group sizes are sufficient to identify significant differences. 
 
Section 10.  Procedures  
 
Please describe in detail all of the procedures you will be doing with animals below. Indicate whether infectious 
agents, chemical or physical restraint, radioactivity or adjuvants will be used. Describe possible/known side effects 
of each procedure. 
 
10.1 Prolonged physical restraint (> 30 minutes) that will be used under this protocol. 
 
10.1.1 How is the animal acclimated to the restraint device?  NA 
10.1.2 Describe the monitoring of the animal during the time of restraint.  NA 
10.1.3 In the event of an animal welfare issue, what are the criteria for removal of the animal from the 
restraint device? NA 
  
10.2 Non-surgical procedures that will be used under this protocol.  
Non-surgical Procedures Description and Guidance 
Describe each non-surgical procedure that will be used and state the maximum number of times each 
procedure will be done to any animal.  
 Please see 8.1 for complete research description.  Each procedure (e.g,. muscle injury) will be  done 
one time per animal. 
 
10.3 Surgical procedures that will be used under this protocol. 
Surgical Procedures Description and Guidance 
Please indicate if surgical procedures will be used under this protocol 
 Yes   
  No (If No, then skip to Question 11) 
 
10.3.1 Review the ASEPTIC TECHNIQUE FOR ANIMAL SURGERY. 
I will adhere to the standards specified in this policy. 
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 Yes   
  No (If no, scientifically justify below*) 
 
 
10.3.2 Review the PREPARATION OF SURGICAL INSTRUMENTS, DEVICES, AND SUPPLIES 
POLICY.  
I will adhere to the standards specified in this policy. 
 Yes   
  No (If no, scientifically justify below*) 
 
 
10.3.3 Describe surgical procedures that will be used. Indicate type of surgery, provide a general 
description and indicate if it will be survival (indicate major or minor) or non-survival surgery. 
. 
 
10.3.3.1 Describe pre- and post-op procedures and monitoring.  
10.3.3.2 Will analgesics will be given pre- or post-procedurally?  
10.3.3.3If analgesics are not used, justify why this is the case.  
10.3.3.4 If sutures or wound clips will be used, indicate when they will be removed.  
10.3.3.5 If multiple major surgeries in a single animal are proposed, please scientifically 
justify the necessity.  
10.3.3.6. If multiple surgeries (major or minor) in a single animal are proposed, please 
indicate the minimum time interval between surgeries.  
10.3.4 Describe any non-pharmacological control of pain post procedure such as: 
 quiet darkened recovery area; and/or 
 increased ambient warmth; and/or  
 soft resting surface, etc.; or 
 other; please explain:  
 
SECTION 11.  Substance Administration 
 
11.1 Substance Description 
If anesthetics, analgesics, or other substances are administered during the conduct of a procedure, please 
describe: Please copy and paste the set of questions as needed to list each additional substance(s) to be 
administered.  
 
11.1.1 Name of Substance:  Ethanol 
11.1.2 Is this a non-pharmaceutical grade chemical or substance?  No 
 If yes, please justify and indicate how sterility and purity are achieved.  
11.1.3 Dose:   up to 20% v/v diluted in drinking water 
11.1.4 Route of Administration:   oral 
11.1.5 Frequency of administration:   daily 
11.1.6 If applicable, state how anesthetic depth will be assessed:  NA 
 
11.1.1 Name of Substance:   S-adenosyl methionine (SAMe) 
11.1.2 Is this a non-pharmaceutical grade chemical or substance?  yes 
 If yes, please justify and indicate how sterility and purity are achieved.  S-adenosyl methionine   
 is delivered as Denosyl provided by NutraMax Laboratories, Inc. This company specializes in   
 animal nutrition. Our colleagues have used Denosyl and report no untoward side effects. 
11.1.3 Dose:   0.4% w/v 
11.1.4 Route of Administration:   oral 
11.1.5 Frequency of administration:   daily, up to 28 days following injury 
11.1.6 If applicable, state how anesthetic depth will be assessed:  NA 
 
11.1.1 Name of Substance:   Barium chloride 
11.1.2 Is this a non-pharmaceutical grade chemical or substance?  yes 
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If yes, please justify and indicate how sterility and purity are achieved.  A pharmaceutical grade BaCl2 
solution is not available.  Working BaCl2 solution is prepared fresh and under the hood on the morning of 
the procedure.  Working solution is diluted in sterile PBS and passed through a filter before being 
introduced into the animal. 
11.1.3 Dose:   1.2% in sterile PBS delivered in 50ul 
11.1.4 Route of Administration:   i.m. 
11.1.5 Frequency of administration:   once on the day of muscle injury 
11.1.6 If applicable, state how anesthetic depth will be assessed:  NA 
 
11.1.1 Name of Substance:   BrdU 
11.1.2 Is this a non-pharmaceutical grade chemical or substance?  no 
 If yes, please justify and indicate how sterility and purity are achieved.  
11.1.3 Dose:   i.p.: 100 ug/g, maxiumum volume 0.3 ml followed by oral: 0.8 mg/ml drinking water 
11.1.4 Route of Administration:   i.p. and oral 
11.1.5 Frequency of administration:   i.p.: twice on day of injury, separated by 8 hours, oral: daily for up to 7 
days 
11.1.6 If applicable, state how anesthetic depth will be assessed:  NA 
 
11.1.1 Name of Substance:   Isoflurane 
11.1.2 Is this a non-pharmaceutical grade chemical or substance?  no 
 If yes, please justify and indicate how sterility and purity are achieved.  
11.1.3 Dose:   2l O2/min flow rate 
11.1.4 Route of Administration:   inhalant 
11.1.5 Frequency of administration:   once on the day of muscle injury 
11.1.6 If applicable, state how anesthetic depth will be assessed:  toe pinch, righting reflex 
 
 
SECTION 12.  Personnel and Their Experience and Training 
 
List the experience and/or training of the personnel and the procedures that each will conduct below. If 
personnel are not experienced, please list the name of the individual(s) who will be responsible for training 
on all procedures.  Please note that DAR and/or the IACUC reserve the right to observe procedures being 
performed prior to protocol approval. 
 
If training has not been completed, visit http://www.gsu.edu/research/iacuc.html and click on “How to 
Enroll in and Use the AALAS Learning Library”.  Complete the Required Education  SECTION prior to 
submitting this protocol application.  
 
All employees of Georgia State University who work with vertebrate animals must enroll in the Medical 
Monitoring Program for Vertebrate Animal Exposure whether or not they chose to participate. To enroll 
click on the following link: http://www.gsu.edu/images/vp_research/MMPVAE_Enrollment_Form.pdf 
 
 Principal Investigator: 
Name:   Jeffrey S. Otis, PhD 
Phone number and location:   TBD – start date at GSU is August 19, 2013 
Procedures will do on animals:   All 
Experience:   15+ years working with animals models of myopathy.  8+ years working with chronic 
alcohol ingestion and glutathione supplementation models in rodents. 2+ years experience working with 
muscle injury and BrdU models.  
GSU training completed:   Yes 
Is this person enrolled in the Medical Monitoring Program for Vertebrate Animal Exposure?  
 yes   
 no   If “no”, see above. 
 
Note: You can copy and paste the set of questions as needed to list additional personnel.   
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 Postdoctoral personnel: 
Name:  NA 
Phone number and location:   
Procedures will do on animals:   
Experience (Indicate who will be responsible for training):   
GSU training completed:   
Is this person enrolled in the Medical Monitoring Program for Vertebrate Animal Exposure? 
 yes   
 no   If “no”, see above 
 
Graduate Students: 
Name:  None yet, but they will be added to the protocol as any interested students join the lab 
Phone number and location:   
Procedures will do on animals:   
Experience (Indicate who will be responsible for training):   
GSU training completed:   
Is this person enrolled in the Medical Monitoring Program for Vertebrate Animal Exposure? 
 yes   
 no   If “no”, see above 
 
Technicians: 
Name:  NA 
Phone number and location:   
Procedures will do on animals:   
Experience (Indicate who will be responsible for training):   
GSU training completed:   
Is this person enrolled in the Medical Monitoring Program for Vertebrate Animal Exposure? 
 yes   
 no   If “no”, see above 
 
Undergraduates: 
Name:  NA 
Phone number and location:   
Procedures will do on animals:   
Experience (Indicate who will be responsible for training):   
GSU training completed:   
Is this person enrolled in the Medical Monitoring Program for Vertebrate Animal Exposure? 
 yes   
 no   If “no”, see above 
 
SECTION 13.  Hazard Use 
 
All Hazardous Materials used must be identified. 
For more information on the Biosafety program please click: GSU Biosafety Program. 
For more information on the Radiation Safety program please click: GSU Radiation Safety. 
For more information on Lab Safety and Hazard Communication please click: GSU Lab Safety and Hazard 
Communication. 
13.1 Are you working with infectious agents and/or biologically-derived toxins? 
   No 
   Yes  I have approval from the Biosafety Committee 
Date: ______________ Approval #   ________________ 
 
13.1.1  Describe all special precautions recommended for personnel who handle animals, equipment, or 
do housekeeping. Describe how contaminated caging or tanks, bedding, and equipment should be 
handled. 
 
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13.2  Does the project use any recombinant DNA (i.e. cloning/expression systems, viral vectors, etc.) material in 
animals? 
    No 
   Yes  I have approval from the Biosafety Committee 
Date: ______________ Approval #   ________________ 
 
13.2.1  Describe all special precautions recommended for personnel who handle animals, equipment, or 
do housekeeping. Describe how contaminated bedding, cages or tanks or equipment should be 
handled. 
 
 
13.3  Will any carcinogenic or toxic compounds to be used in animals? 
   No 
   Yes   
BrdU usage has received IRB approval.  Approval date is August 26, 2013. 
 
13.3.1  Describe all special precautions and training recommended for personnel who handle animals, 
equipment, or do housekeeping.  Describe how contaminated caging or tanks, bedding, and 
equipment should be handled. 
All personnel working with animals must successfully complete GSU training (e.g., working 
with mice, biosafety).  Biological tissues will be disposed of in appropriate biohazard bags.  
Sharps will be disposed of in appropriate sharps containers in the lab.  Cages and bedding will be 
returned to DAR facilities for processing – no special considerations are required for this protocol.  
Personnel working with BrdU will be trained by the PI.  Appropriate signage will clearly indicate 
BrdU use (in storage form and in drinking bottles). 
 
13.4  Will any radioactive compounds be administered to the animals?   
   No 
   Yes  I have approval from the Radiation Safety Committee 
Date: ______________ Approval #   ________________ 
 
13.4.1  Describe all special precautions recommended for personnel who handle animals, equipment, or 
do housekeeping.  Describe how contaminated caging, bedding, and equipment should be handled. 
 
 
13.5  Will Controlled Substances be used? 
   No 
   Yes 
 
13.5.1  Do you have a Controlled Substance Permit? 
   No 
   Yes 
 
SECTION 14.  Animal Housing and Husbandry 
 
14.1  Will you breed these animals? See OLAW Position Statement 2c) Rodent Housing and GSU IACUC 
Standard Operating Procedures on Social Housing of Social Species. 
   No 
  Yes  Please address the following: describe method of mating (harem, monogamous, et cetera); 
describe age of weaning; describe genetic monitoring and methods to assure inbred / outbred status; justify 
breeding versus obtaining commercially. If only one sex of offspring will be used in experiments, please 
justify. A separate breeding protocol (Use breeding protocol form) may be submitted to generate animals 
for this and other experimental protocols.  
 
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14.1.1 If breeding Genetically Modified Animals (GMAs), with their inherent potential for unanticipated 
phenotypes, please describe monitoring procedures for unexpected outcomes:  
 
14.1.2 Please state if there is a plan in place for preservation of critcal or irreplaceable animals such as 
transgenics:  
 
14.2  Do the animals require housing other than standard caging/bedding or tanks/water? 
  No 
   Yes (List housing required and explain below): 
 Mice in the voluntary wheel running groups are housed individually in modified rat cages.  This is 
required as measurements are taken from one mouse at a time.   
14.3 Will animals be housed singly?  Yes, see 14.2 for explanation. 
Non-Human Primate Housing and Social Housing of Social Species criteria options can be found at GSU 
IACUC Standard Operating Procedure on Social Housing of Social Species and OLAW Position Statement 
2a Nonhuman Primate Housing. 
 
14.4 Do the animals require special care? 
   No 
   Yes (List special care and explain below) 
 
 
14.5  Do the animals require diet other than the standard diet for this species used at GSU? 
   No 
  Yes (List diet and explain below) 
 A significant percentage of our animals will be on an alcohol diet.  This diet will be replenished 
 and tracked by the PI.  Appropriate signage will clearly indicate to the DAR staff that a special diet 
 is in use and that the PI should be contacted with any questions or issues. 
14.6 Will food and/or fluid restriction and/or regulations be necessary? 
   No 
  Yes (List restrictions and explain below how they will be managed).  
Describe how the animal(s) will be monitored to ensure that food and fluid intake meets their nutritional 
needs.  In our vast experience with these models, animals gain weight comparable to controls.  
Therefore, we do not routinely check body weight to ensure adequate nutrition.  Regardless, water is 
replenished every 1-2 weeks. 
 
14.7  Will animals remain outside the IACUC approved Animal Housing Area for more than 12 hours? 
   No 
  Yes (List building and room number and explain below) 
 
 
14.8  Will animals be transported outside of an IACUC approved Animal Housing Area (e.g. to your lab or off 
campus)? 
 Yes   
 I agree to adhere to the GSU IACUC Animal Transportation Policy.  
 I request a deviation from the GSU IACUC Animal Transportation Policy. Please state the 
deviation and provide a justification for the deviation below:.  
 
  No  
 
14.9  Will animals undergo experimental manipulations outside the IACUC approved Animal Housing Area? 
  Yes (List building and room number and explain below) 
 Room to be names, but it is next to Dr. Chris Ingalls’ lab in the basement of the Sports Arena (G19)  
 
   No 
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14.10  Can animals be provided environmental enrichment? See OLAW Position Statement 2b) Environmental 
Enrichment for more information. Enrichment options can be found at: Enrichment Options 
   Yes (List enrichment requested below)  
 group housing, nestlets, voluntary free wheels for singly housed mice 
   No (Explain below)  
 
 
 
IACUC Original Protocol 
 
GEORGIA STATE UNIVERSITY 
INSTITUTIONAL ANIMAL CARE AND USE COMMITTEE 
Request for Amendment to an Approved Protocol 
Information for the protocol you wish to amend: 
Protocol Number: A13025 (0816) 
Principal Investigator: Jeffrey S. Otis, PhD  
Department: Kinesiology and Health 
Protocol Title: Alcoholic myopathy and skeletal muscle regeneration 
Animal Type and Quantity: Mouse 
Proposal Period: 8/23/2016 
1. I wish to amend this protocol by making the following changes: 
   This amendment is requesting the addition of in vivo isometric torque measurements made in our mouse 
model. 
 
2. Please provide scientific justification for the changes 
       In the approved parent protocol and its amendment, we are interested in quantifying improvements in skeletal 
muscle regeneration following nutritional supplementation with S-adenosyl methionine (parent)  and/or 
resveratrol (amendment).  To do this, we have relied solely on histochemical analyses of regenerated fiber 
cross-sectional area and fibrosis post-injury.  Here, we would like to add physiological measures of skeletal 
muscle performance (i.e., isometric torque).  These measures complement our histochemical outcomes and 
give us a better idea of the true structure-function relationship within regenerating muscle. 
 
        Proposed experimental procedure in detail: 
Isometric torque of the anterior crural muscles will be measured in vivo immediately before and at the 
end of 2, 7, 14, and 28 days of muscle recovery following barium chloride-induced tissue injury.  
Depending on group, isometric torque measures may occur in a single mouse from 2-5 times. 
 
Immediately before testing, mice will be anesthetized with isoflurane (5% induction 1000 ml/min of 
100% medical grade oxygen and 1-2% maintenance in 500 ml/min of 100% medical grade oxygen).  
Depth of anesthesia will be assessed by absence of toe pinch reflex and rate/depth of respiration.  Body 
temperature will be maintained via heating pad.  Hair will be removed using clippers and then the skin 
covering the biceps femoris and lateral gastrocnemius muscles will be aseptically prepared.  Once 
complete, the mouse will be transferred and secured (tail, forelimbs, and contralateral hindlimb) to a 
temperature-controlled platform.  The ankle and knee of the experimental hindlimb will be held in place 
using a clamp device as previously described (J. Appl. Physiol. 79:1260, 1995).  Two sterilized 
platinum subdermal needle electrodes will be inserted into the skin proximal to the common peroneal 
nerve.  Anterior crural muscle strength will be measured by stimulating the common peroneal nerve via 
the electrodes.  Torque will then be measured at the following stimulation frequencies: 20, 40, 60, 80, 
100, 125, 150, 200, 250, 300, 350, and 400 Hz.  Mice will be identified via ear hole punch for 
subsequent torque measures.  Depending on group, mice will be returned to their cages and monitored 
for recovery from anesthesia, or sacrificed as described in the parent protocol. 
 
Importantly, the isometric torque test is well-tolerated by the mice and does not result in ill-effects on 
health (i.e., loss of body mass, poor appetite, failure to groom, loss of muscle function in the tested 
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limb).  Finally, multiple anesthetic bouts are well-tolerated in mice. 
 
3. Justification for non-duplication of work.  
Please provide a written assurance that the proposed work is not unnecessarily duplicative. 
       We have search Pubmed (February 5, 2014) and have concluded that performing in vivo isometric  torque 
analyses in our mouse model of alcoholic myopathy +/- injury +/- SAMe +/- resveratrol is completely novel 
and does not duplicate previous work.  
 
4. Personnel:  If new procedures are proposed, list the name(s), experience and/or training of the personnel and the 
procedures that each will conduct.  List the names(s) of the individuals who will be responsible for training:   
     I have submitted a personnel amendment application to include Cory Baumann and Russell Rogers. They are 
PhD students in the laboratory of Chris Ingall and have extensive knowledge, training, and expertise with 
the in vivo isometric torque model.  Importantly, these techniques mirror the approved protocol of Dr. 
Ingalls (#A12045). 
 
 
5. Highest Pain Category for experiments described in this amendment:  (enter B, C, D, or E) 
Class D.   
Please note, however, that the approved parent protocol categorizes animals undergoing skeletal muscle injury via 
BaCl2 injection as Class E.   
 
USDA Classifications and Examples of Pain Categories: 
Classification B: Animals being bred, conditioned, or held for use in teaching, testing, experiments, research, or 
surgery, but not yet used for such purposes. 
Classification C: Animals upon which teaching, research, experiments, or tests will be conducted involving no pain, 
distress, or use of pain-relieving drugs. 
Classification D: Animals upon which experiments, teaching, research, surgery, or tests will be conducted 
involving accompanying pain or distress to the animals and for which appropriate anesthetic, analgesic, or 
tranquilizing drugs will be used. 
Classification E: Animals upon which teaching, experiments, research, surgery, or tests will be conducted involving 
accompanying pain or distress to the animals and for which the use of appropriate anesthetic, analgesic, or 
tranquilizing drugs will adversely affect the procedures, results, or interpretation of the teaching, research, 
experiments, surgery, or tests. 
Is this a change in Pain Category?  Yes    No 
 
6. If the Pain Category Is “B” or “C” please go to question number 8. 
7. Explanation for the Consideration of Alternatives for Category “D” or “E” Animal Use.  
Federal Regulations (The Public Health Service Policy and the Animal Welfare Act) and University Policy 
require assurance that this project does not unnecessarily duplicate research projects/courses performed at this or 
other institutions, and that the use of alternatives to live animal models and alternative procedures that may cause 
more than momentary or slight pain/distress (Class “D” and “E” procedures) to animals have been considered. 
The information in this section should include adequate information for the IACUC to assess that a reasonable 
and good faith effort was made to determine the availability of alternative models or methods.  
The following is a guide for answering 7.1 and beyond. 
Your literature search is done as part of the OLAW requirement to address the “3Rs”  
(Refinement, Reduction, and Replacement) issues.  For example:  
* Refinement of procedures to eliminate or minimize pain or distress, the use of remote telemetry to decrease 
the distress of restraint; the use of humane endpoints. 
Other examples of refinement are: ways to enhance the well-being of animals and the use of analgesics to 
decrease pain or anesthetics to decrease distress. 
For the literature searches 
Ask "Am I using the least painful technique(s)?” 
 - Search terms: Your species + animal/experimental model/technique + scientific keywords 
* Replacement of live animals with non-animal procedures or a less sentient species. Examples include the use 
of non-animal models such as in-vitro work, cell culture, tissues culture, computer models or simulations.  
Ask "Do I need to use animals?": 
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 - Search terms: Your experimental model + simulation + in vitro +scientific keywords  
Ask "Am I using the lowest species possible?": 
 - Search terms: Your species + all applicable lower species (For example if using mice, specifically use 
"invertebrate", "fish" and "frog" in your search terms) + your animal/experimental model + scientific keywords 
Note: There are NO search terms that will direct the searcher to all examples of replacement or 
refinement. The onus is on the researcher to read and evaluate the literature.  
 
*Reduction in the number of animals used in the study. (This only needs to be addressed in Question 14 
below).  Examples include the use of shared control groups; preliminary screening in non-animal systems; 
innovative statistical packages.  
The selection of databases depends on the work performed and the species used in the protocol. Samples of 
databases available through the Georgia State University Library www.library.gsu.edu/database web pages 
· PubMed·   Web of Knowledge · Biological Abstracts·   Web of Science    PsychINFO    AltWeb    NLM Gateway     
AVAR     Galileo     AGRICOLA 
 OVID (allows a search of multiple databases including Agricola, BIOSIS, CAB Abstracts, Medline, Zoological 
Record, etc.)  
Please visit the Animal Welfare Information Center (AWIC) Literature Searching and Databases page 
(http://awic.nal.usda.gov/nal_display/index.php?tax_level=1&info_center=3&tax_ subject=184) for a list of 
databases that can be used to search for alternatives. The AWIC site also recommends using the Literature 
Search Worksheet (http://www.nal.usda.gov/awic/alternatives/searches/altwksht.pdf) to assist in performing a 
successful alternatives database search. The worksheet helps to identify relevant searchable terms and concepts. 
 
7.1 Literature search for alternatives to painful procedures 
If you chose category “D” or “E” above, please do literature searches using the broadest database for your area 
of study, and provide a brief summary of the results obtained to verify that you investigated the use of 
alternatives to painful or distressful procedures. If you have not selected either category D or E, skip to section 
6.2. 
 
 
7.1.1 Name of the databases used:   Pubmed, ALTBIB 
Date the databases search(es)  were done:   February 5, 2014 
Did the search cover the entire date range of the databases with no restriction on dates? 
 Yes   
  No (If No, provide dates covered by the search(es) below) 
Dates covered by the databases search(es):   
 
7.1.2 Search keyword(s) used: include number of hits for combinations of terms. You must use 
‘alternative’ and ‘animal welfare’ in the search combinations for invasive or painful 
procedures (See above for 3R criteria.) 
 alcoholic myopathy, skeletal muscle regeneration, skeletal muscle injury, animal testing 
 alternatives, animal welfare, isometric torque, and alternative 
(1) Alcoholic myopathy + animal welfare = 0 
(2) Alcoholic myopathy + alternative = 0 
(3) Skeletal muscle regeneration + animal welfare = 0 
(4) Skeletal muscle regeneration + alternative = 10 
(5) Skeletal muscle injury + animal welfare = 0 
(6) Skeletal muscle injury + alternative = 5 
(7) Skeletal muscle injury + isometric torque + animal welfare = 0 
(8) Skeletal muscle injury + isometric torque + alternative = 1 
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71.3 Summarize the information found in the hits below.  (Note: this should be a general summary. 
You do not need to go into the details of each hit but rather summarize hits by relevant groups)  
 Search 8 returned 1 hit and was not an alternative to animal use, but described torque 
measurements in human subjects. 
 
 
7.1.4 Explain what alternatives exist in place of using animals for this protocol and provide a 
justification if these cannot be used.  
 Alternatives do not include less sentient species.  Similarly, alternatives are limited to in 
vitro systems that do not adequately reflect the complex physiological response that 
occurs in vivo.  
 
7.1.5 Other Sources of Information on Alternatives to Painful Procedures 
7.1.5.1  Consultation with Experts: (Names, credentials, and dates):    
(1) Mike Huerkamp, DVM 2005-2013.  I sat on the Emory IACUC for 4 years and had frequent  
conversations with Mike (Director of DAR) and other IACUC members about animal welfare. 
(2) Chris Ingalls, PhD.  I have discussed adding this procedure to my protocol with Dr. Ingalls 
and his graduate students, Cory Baumann and Russell Rogers. 
 
7.1.5.2  Scientific Meetings: Specify:   NA 
 
Note: A careful literature search is usually the best way to determine whether a proposed study is unnecessarily 
duplicative of previous work. However, it is ok to repeat a published experiment to make sure that it works in a 
different lab. This reason just needs to be stated as the justification.  
 
8. If additional animals are needed, please justify their use.  
Note: This Amendment Form may be used to request additional animals. If a different species is required you 
must submit a new protocol. 
We are NOT requesting additional animals to assess the effects of our injury or treatments on isometric torque.  All 
animals currently approved will be subject to isometric torque measures as described below (modified from 
approved protocol A12045, PI: Ingalls). 
 
 
9. Are there any changes in the Animal housing/husbandry for this protocol?  
If so please describe below 
  NA 
 
Jeffrey S. Otis 
____________________________________________February 5, 2014________ 
Investigator’s Signature                                                         Date 
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IACUC Original Protocol 
 
GEORGIA STATE UNIVERSITY 
INSTITUTIONAL ANIMAL CARE AND USE COMMITTEE 
Request for Amendment to an Approved Protocol 
Information for the protocol you wish to amend: 
Protocol Number: A13025  
Principal Investigator: Jeffrey S. Otis, PhD  
Department: Kinesiology and Health 
Protocol Title: Alcoholic myopathy and skeletal muscle regeneration 
Animal Type and Quantity: Mouse 
Proposal Period: end date of approved parent protocol is 8/23/2016 
1. I wish to amend this protocol by making the following changes: 
   This amendment requests: (1) a new drug, 17-allylamino-17-demethoxygeldanamycin (17AAG), to be delivered 
to mice i.p., and (2) an additional 150 mice.    
 
 
2. Please provide scientific justification for the changes 
Rationale 
We are currently approved to injure tibialis anterior muscles of mice with intramuscular injections of 1.2% BaCl2 to 
study the mechanisms of degeneration and regeneration.  Recent work has suggested that early inflammatory events 
following injury (e.g, cytokine induction) may play a crucial role in the successful repair of damaged muscle fibers1.  
Accordingly, this amendment requests the use of 17AAG, an inhibitor of heat shock protein 90 (HSP90), to 
subsequently modulate the inflammatory cytokine, NFκB.  Specifically, 17AAG binds HSP90, which then allows 
for heat shock transcription factor 1 (HSF1) to translocate into the muscle cell nucleus.  HSF1 binds to HSF1 
response elements and increases HSP70 expression2,3 which has been shown to significantly reduce NFκB activity5.  
17AAG treatment has been shown to enhance recovery following contraction-induced injury in old muscles3 and 
attenuate atrophy following unloading4, however, it is unclear if these findings extend to otherwise, healthy young 
mice.  Further, these experiments will lay the foundation for our subsequent studies using the chronic alcohol model 
and the effects of HSP70 on regeneration. 
 
Experimental Design and Methods  
The overall goal of this proposal is to identify the role of HSP70 and NFκB on the regenerative response of injured 
skeletal muscle following injury.  To accomplish this, mice will be randomly assigned to one of two groups 
(n=75/group): (1) Injured, vehicle-injected, or (2) Injured, allylamino-17-demethoxygeldanamycin (17AAG)-
injected.  Contralateral (uninjured) muscles will serve as controls.  Mice in treatment group will receive 100-µl of 
17AAG (40 mg/kg, i.p.) suspended in dimethyl sulfoxide 3 days prior to a BaCl2-induced injury.  17AAG will be 
sterile filtered using .22µm filters prior to injection.  This dose of 17AAG and route of delivery has been shown to 
result in 99% bioavailability of drug in skeletal muscle6.  Depending on group, mice may receive up to 4 injections 
of 17AAG (initial injection, and once every 7 days for up to 3 weeks) as previously described2.  Thus, injections will 
occur 4, 11 and 18 days following the BaCl2 injury.  The figure below displays our experimental timeline for 
17AAG injection (treatment), muscle injury (BaCl2 injection at time 0), and animal sacrifice and muscle excision.   
  
Again, uninjured, contralateral TA muscles from 17AAG
any effect on the unstressed TA muscles.  Likewise, vehicle
mice will serve as the uninjured controls as we have previously described
control greatly reduces the animal numbers required to calculate meaningful statistical diffe
 
Monitoring:  We do not expect significant untoward effects of 17AAG administration.  For example, Lomonosova 
has reported no change in body weight of rodents that received similar concentrations of the drug.  Regardless, we 
will monitor our mice three times per week for any signs of distress (e.g., failure to groom).  In addition, we will 
work closely with the DAR room staff to identify any (although unexpected) signs of distress and request 
euthanization of any ill-affected animal accordingly.
 
Approved procedures for the parent protocol (in brief)
Muscular function will be determined by assessing 
(tibialis anterior; TA, extensor digitorum longus and extensor hallucis muscles) immedia
injury, and 7, 14 or 21 days into recovery.  Mice will be sacrificed at 1, 3, 7, 14 or 21 days post
point) and the TA muscles will be excised.  Within each time point, five mice will have their TA muscles mounted 
in a medium (O.C.T., Merck, UK), frozen rapidly in 2
histological analysis.  The remaining 10 mice from each group will have their TA muscles rapidly frozen in liquid 
nitrogen and stored at −80°C until biochemical analysis. 
 
References: 
1. Otis JS, Niccoli S, Hawdon N, Sarvas JL, Frye MA, Chicco AJ, 
myoblast proliferation. PLoS One. 2014; 9(3):e92363.
 
 
3. Justification for non-duplication of work. 
Please provide a written assurance that the proposed work is not unnecessarily duplicative.
 17AAG has been proven effective in an animal model of advanced age.  However, the biochemistry and 
physiology of muscle regeneration is comparatively different in an otherwise healthy, younger animal.  No 
research exists on the impact of HSP70 modulation on skeletal muscle physiology, inflammation, oxidant 
stress, nor NFkB-dependent signaling following chemical
the foundation for treatment paradigms that improve skeletal muscle repair and hasten the return of optimal 
muscle health following significant trauma.
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-injected mice will be assessed to determine if the drug has 
-treated contralateral TA muscles from vehicle
1
.  Using the contralateral muscle as the 
rences.
 
 
in vivo isometric torque produced by the anterior crural muscles 
tely before the BaCl
-injury (n=15/time 
-methylbutane cooled in liquid nitrogen, and sectioned for 
 
Lees SJ. Pro-inflammatory  mediation of 
 
 
 
-induced injury.  These experiments could provide 
 
 
-injected 
 
2 
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4. Personnel:  If new procedures are proposed, list the name(s), experience and/or training of the personnel and the 
procedures that each will conduct.  List the names(s) of the individuals who will be responsible for training:   
 Cory Baumann (PhD student) is currently approved on the parent protocol and will be responsible for 17AAG 
injections.  Cory has approximately 5 years of reseach experience that requires animal handling, small 
animal surgery, and animal care.  He has been adequately trained on these techniques by Chris Ingalls.  In 
addition, Cory intends to contact Matt Davis to re-train on scruff techniques. 
 
 
5. Highest Pain Category for experiments described in this amendment:  (enter B, C, D, or E) 
Class C.   
 
Please note, however, that the approved parent protocol categorizes animals undergoing skeletal muscle injury via 
BaCl2 injection as Class E.  As the contralateral TA muscle is used as the control, all mice receive BaCl2 injection 
on one limb. 
 
USDA Classifications and Examples of Pain Categories: 
Classification B: Animals being bred, conditioned, or held for use in teaching, testing, experiments, research, or 
surgery, but not yet used for such purposes. 
Classification C: Animals upon which teaching, research, experiments, or tests will be conducted involving no pain, 
distress, or use of pain-relieving drugs. 
Classification D: Animals upon which experiments, teaching, research, surgery, or tests will be conducted 
involving accompanying pain or distress to the animals and for which appropriate anesthetic, analgesic, or 
tranquilizing drugs will be used. 
Classification E: Animals upon which teaching, experiments, research, surgery, or tests will be conducted involving 
accompanying pain or distress to the animals and for which the use of appropriate anesthetic, analgesic, or 
tranquilizing drugs will adversely affect the procedures, results, or interpretation of the teaching, research, 
experiments, surgery, or tests. 
Is this a change in Pain Category?  Yes    No 
 
6. If the Pain Category Is “B” or “C” please go to question number 8. 
7. Explanation for the Consideration of Alternatives for Category “D” or “E” Animal Use.  
Federal Regulations (The Public Health Service Policy and the Animal Welfare Act) and University Policy 
require assurance that this project does not unnecessarily duplicate research projects/courses performed at this or 
other institutions, and that the use of alternatives to live animal models and alternative procedures that may cause 
more than momentary or slight pain/distress (Class “D” and “E” procedures) to animals have been considered. 
The information in this section should include adequate information for the IACUC to assess that a reasonable 
and good faith effort was made to determine the availability of alternative models or methods.  
The following is a guide for answering 7.1 and beyond. 
Your literature search is done as part of the OLAW requirement to address the “3Rs”  
(Refinement, Reduction, and Replacement) issues.  For example:  
* Refinement of procedures to eliminate or minimize pain or distress, the use of remote telemetry to decrease 
the distress of restraint; the use of humane endpoints. 
Other examples of refinement are: ways to enhance the well-being of animals and the use of analgesics to 
decrease pain or anesthetics to decrease distress. 
For the literature searches 
Ask "Am I using the least painful technique(s)?” 
 - Search terms: Your species + animal/experimental model/technique + scientific keywords 
* Replacement of live animals with non-animal procedures or a less sentient species. Examples include the use 
of non-animal models such as in-vitro work, cell culture, tissues culture, computer models or simulations.  
Ask "Do I need to use animals?": 
 - Search terms: Your experimental model + simulation + in vitro +scientific keywords  
Ask "Am I using the lowest species possible?": 
 - Search terms: Your species + all applicable lower species (For example if using mice, specifically use 
"invertebrate", "fish" and "frog" in your search terms) + your animal/experimental model + scientific keywords 
Note: There are NO search terms that will direct the searcher to all examples of replacement or 
refinement. The onus is on the researcher to read and evaluate the literature.  
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*Reduction in the number of animals used in the study. (This only needs to be addressed in Question 14 
below).  Examples include the use of shared control groups; preliminary screening in non-animal systems; 
innovative statistical packages.  
The selection of databases depends on the work performed and the species used in the protocol. Samples of 
databases available through the Georgia State University Library www.library.gsu.edu/database web pages 
· PubMed·   Web of Knowledge · Biological Abstracts·   Web of Science    PsychINFO    AltWeb    NLM Gateway     
AVAR     Galileo     AGRICOLA 
 OVID (allows a search of multiple databases including Agricola, BIOSIS, CAB Abstracts, Medline, Zoological 
Record, etc.)  
Please visit the Animal Welfare Information Center (AWIC) Literature Searching and Databases page 
(http://awic.nal.usda.gov/nal_display/index.php?tax_level=1&info_center=3&tax_ subject=184) for a list of 
databases that can be used to search for alternatives. The AWIC site also recommends using the Literature 
Search Worksheet (http://www.nal.usda.gov/awic/alternatives/searches/altwksht.pdf) to assist in performing a 
successful alternatives database search. The worksheet helps to identify relevant searchable terms and concepts. 
 
7.1 Literature search for alternatives to painful procedures 
If you chose category “D” or “E” above, please do literature searches using the broadest database for your area 
of study, and provide a brief summary of the results obtained to verify that you investigated the use of 
alternatives to painful or distressful procedures. If you have not selected either category D or E, skip to section 
6.2. 
   
7.1.1 Name of the databases used:    
Date the databases search(es)  were done:    
Did the search cover the entire date range of the databases with no restriction on dates? 
 Yes   
  No (If No, provide dates covered by the search(es) below) 
Dates covered by the databases search(es):   
 
7.1.2 Search keyword(s) used: include number of hits for combinations of terms. You must use 
‘alternative’ and ‘animal welfare’ in the search combinations for invasive or painful 
procedures (See above for 3R criteria.) 
 
71.3 Summarize the information found in the hits below.  (Note: this should be a general summary. 
You do not need to go into the details of each hit but rather summarize hits by relevant groups)  
 
 
7.1.4 Explain what alternatives exist in place of using animals for this protocol and provide a 
justification if these cannot be used.  
 
7.1.5 Other Sources of Information on Alternatives to Painful Procedures 
7.1.5.1  Consultation with Experts: (Names, credentials, and dates):    
7.1.5.2  Scientific Meetings: Specify:    
 
Note: A careful literature search is usually the best way to determine whether a proposed study is unnecessarily 
duplicative of previous work. However, it is ok to repeat a published experiment to make sure that it works in a 
different lab. This reason just needs to be stated as the justification.  
 
8. If additional animals are needed, please justify their use.  
Note: This Amendment Form may be used to request additional animals. If a different species is required you 
must submit a new protocol. 
Here, we request an additional 150 mice to be grouped as: 
 
(1) Injured, vehicle-injected (n=75) 
(2) Injured, allylamino-17-demethoxygeldanamycin (17AAG)-injected (n=75) 
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Within each group, 15 animals will be sacrificed at 5 different time points post-injury (i.e., 1, 3, 7, 14 or 21 days).  
Harvested tissues will then be subjected to various histological or biochemical analyses.  Again, please see figure 
above for clarification. 
 
 
9. Are there any changes in the Animal housing/husbandry for this protocol?  
If so please describe below 
  No 
 
Jeffrey S. Otis 
__________________________________________August 15, 2014________ 
Investigator’s Signature                                                          Date 
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Appendix B: Raw Data 
 
In Vivo Data 
 
Subject 
ID Group Day 
BW-
Pre 
BW-
Post L-TA R-TA 
Absolute 
Torque-Pre 
Absolute 
Torque-Post 
Normalized 
Toque-Pre 
Normalized 
Torque-Post 
Torque 
Deficit 
1 VEH 1 
 
22.46 49.13 43.76 
     
2 VEH 1 
 
23.00 52.64 38.20 
     
3 VEH 1 
 
22.03 54.65 40.28 
     
4 VEH 1 
 
24.70 61.35 40.51 
     
5 VEH 1 
 
21.89 43.21 43.14 
     
6 VEH 1 
 
22.27 46.61 33.02 
     
7 VEH 1 
 
23.75 53.70 43.96 
     
8 VEH 1 
 
20.99 47.46 33.21 
     
9 VEH 1 
 
27.34 52.46 49.13 
     
10 VEH 1 
 
26.13 46.73 40.36 
     
11 VEH 1 
 
24.19 49.30 40.76 
     
12 VEH 1 
 
22.11 49.85 41.18 
     
1 HSP 1 
 
22.90 47.45 40.60 
     
2 HSP 1  22.87 46.40 42.00      
3 HSP 1 
 
24.96 54.69 38.83 
     
4 HSP 1 
 
23.47 59.83 39.98 
     
5 HSP 1 
 
21.39 62.04 49.35 
     
6 HSP 1 
 
23.14 47.75 38.07 
     
7 HSP 1 
 
25.21 53.06 43.77 
     
8 HSP 1 
 
22.09 51.64 42.47 
     
9 HSP 1 
 
25.74 59.72 46.62 
     
10 HSP 1 
 
25.19 43.00 49.18 
     
11 HSP 1 
 
22.28 45.02 39.49 
     
1 VEH 3 
 
21.31 52.39 48.56 
     
2 VEH 3 
 
25.11 41.88 41.86 
     
3 VEH 3 
 
27.25 45.21 47.63 
     
4 VEH 3 
 
27.11 38.12 42.40 
     
5 VEH 3 
 
25.90 47.98 47.22 
     
6 VEH 3 
 
24.00 44.47 43.41 
     
7 VEH 3 
 
24.00 46.22 44.83 
     
8 VEH 3 
 
20.90 38.26 39.79 
     
9 VEH 3 
 
24.02 38.93 34.22 
     
10 VEH 3 
 
24.01 52.11 39.97 
     
1 HSP 3 
 
23.86 45.74 45.12 
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2 HSP 3 
 
21.65 41.52 44.56 
     
3 HSP 3 
 
23.32 37.69 45.37 
     
4 HSP 3 
 
23.65 46.42 40.85 
     
5 HSP 3 
 
25.31 41.52 33.02 
     
6 HSP 3 
 
25.20 44.70 46.05 
     
7 HSP 3 
 
22.19 23.56 37.68 
     
8 HSP 3 
 
25.88 43.42 46.53 
     
9 HSP 3 
 
24.99 39.73 46.83 
     
10 HSP 3 
 
23.28 34.25 45.13 
     
11 HSP 3 
 
21.11 33.61 39.32 
     
12 HSP 3 
 
24.60 32.67 32.95 
     
13 HSP 3 
 
21.43 39.03 34.56 
     
14 HSP 3 
 
24.83 43.05 43.30 
     
1 VEH 7 25.17 25.43 38.21 36.61 2.47 1.25 98.17 49.27 49.81 
2 VEH 7 21.54 22.21 30.47 39.34 1.91 0.55 88.68 24.95 71.87 
3 VEH 7 26.01 25.10 31.41 40.28 2.80 0.59 107.78 23.52 78.18 
4 VEH 7 23.80 23.94 34.65 43.20 2.70 0.96 113.41 40.13 64.61 
5 VEH 7 25.03 25.31 40.20 40.28 2.86 0.48 114.21 19.10 83.28 
6 VEH 7 24.51 24.88 30.56 46.07 2.71 0.54 110.36 21.70 80.34 
7 VEH 7 24.64 24.14 38.04 45.63 2.52 0.64 102.17 26.48 74.08 
8 VEH 7 24.04 24.65 36.81 41.34 2.41 1.09 100.36 44.17 55.98 
9 VEH 7 24.43 25.61 35.02 41.14 2.99 0.35 122.33 13.51 88.96 
10 VEH 7 24.20 24.57 30.86 44.53 2.74 0.64 113.36 26.22 76.87 
1 HSP 7 25.51 24.29 36.79 43.36 2.48 0.75 97.15 30.84 68.26 
2 HSP 7 23.90 23.33 35.37 38.20 2.29 0.93 95.79 40.03 58.21 
3 HSP 7 23.36 
   
2.43 
 
103.84 
  
4 HSP 7 24.28 22.50 35.41 40.61 
 
0.59 
 
26.37 
 
5 HSP 7 24.64 25.43 34.75 39.04 2.30 0.70 93.21 27.61 70.38 
6 HSP 7 26.93 28.08 32.11 50.18 2.75 0.30 102.26 10.57 89.66 
7 HSP 7 25.60 25.64 39.74 49.01 
 
0.49 
 
18.94 
 
8 HSP 7 21.60 21.89 24.06 41.01 
 
0.43 
 
19.62 
 
9 HSP 7 24.53 25.51 37.34 44.81 3.06 0.34 124.73 13.18 89.43 
10 HSP 7 25.39 25.04 28.87 53.09 
 
0.46 
 
18.19 
 
11 HSP 7 25.11 26.55 26.51 43.56 2.79 0.63 111.09 23.73 78.64 
1 VEH 14 25.72 25.60 46.21 42.70 2.72 1.88 105.84 73.38 30.67 
2 VEH 14 21.80 22.55 42.89 42.88 2.41 1.73 110.45 76.51 30.74 
3 VEH 14 23.81 24.37 45.24 41.81 2.70 2.01 113.30 82.30 27.36 
4 VEH 14 25.02 26.02 48.40 46.22 2.76 1.97 110.43 75.70 31.45 
5 VEH 14 21.79 23.53 48.87 42.81 2.65 1.78 121.73 75.65 37.86 
6 VEH 14 22.08 22.78 38.39 39.98 2.10 1.51 95.30 66.32 30.41 
7 VEH 14 22.94 23.76 45.60 42.59 2.24 1.98 97.83 83.26 14.90 
 105 
 
8 VEH 14 26.96 27.30 56.02 48.06 2.71 1.81 100.64 66.28 34.14 
9 VEH 14 21.60 22.26 53.45 46.95 2.67 2.03 123.51 91.02 26.31 
10 VEH 14 24.93 26.35 57.41 46.38 2.98 2.39 119.73 90.60 24.33 
1 HSP 14 25.56 25.08 47.42 46.52 2.84 2.09 111.10 83.50 24.84 
2 HSP 14 23.00 24.38 46.56 38.26 2.09 1.80 90.93 73.83 18.81 
3 HSP 14 24.73 23.52 45.92 32.57 2.66 2.04 107.38 86.58 19.37 
4 HSP 14 22.11 23.08 44.14 43.82 2.74 2.06 123.92 89.38 27.87 
5 HSP 14 23.84 24.15 44.91 45.18 2.51 1.61 105.37 66.46 36.93 
6 HSP 14 24.66 26.65 47.86 46.12 2.59 1.89 104.88 70.78 32.51 
7 HSP 14 26.15 28.78 55.70 44.65 3.03 2.24 116.02 77.87 32.88 
8 HSP 14 25.27 26.74 49.05 44.63 2.86 2.02 113.17 75.57 33.22 
9 HSP 14 25.68 25.63 42.78 44.34 
 
1.80 
 
70.29 
 
10 HSP 14 22.96 24.46 44.09 34.75 2.66 1.93 115.68 78.98 31.72 
1 VEH 21 21.26 26.76 65.28 40.23 2.48 2.13 116.74 79.60 31.81 
2 VEH 21 27.39 28.50 73.94 53.74 3.11 2.98 113.67 104.69 7.90 
3 VEH 21 27.47 27.22 57.30 45.40 2.95 2.14 107.46 78.55 26.90 
4 VEH 21 25.11 26.78 56.55 48.77 
 
2.86 
 
106.89 
 
5 VEH 21 26.52 27.45 69.59 42.20 2.67 2.45 100.78 89.25 11.44 
6 VEH 21 23.29 25.69 51.97 31.60 
 
2.57 
 
100.18 
 
7 VEH 21 23.68 25.52 52.21 37.57 2.93 2.49 123.91 97.56 21.26 
1 HSP 21 26.95 27.87 55.85 50.91 2.69 2.44 99.80 87.41 12.42 
2 HSP 21 24.25 25.13 56.17 43.12 2.52 2.61 104.06 103.83 0.22 
3 HSP 21 23.58 23.50 54.23 48.66 2.39 2.07 101.53 88.00 13.32 
4 HSP 21 26.61 27.71 56.01 52.11 3.28 2.47 123.24 89.05 27.74 
5 HSP 21 25.67 26.39 54.08 54.78 2.65 2.81 103.38 106.36 -2.88 
6 HSP 21 27.53 27.11 63.77 45.76 2.97 2.66 107.89 98.06 9.11 
7 HSP 21 21.86 
   
2.42 
 
110.55 
  
8 HSP 21 21.94 24.05 54.40 40.04 2.74 2.24 124.82 93.34 25.22 
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Histology Data 
 
Subject ID Group Day TA CSA 
2 VEH 7 Left 1262 
3 VEH 7 Left 1108 
6 VEH 7 Left 1204 
7 VEH 7 Left 1251 
2 VEH 7 Right 2020 
3 VEH 7 Right 2229 
6 VEH 7 Right 2607 
7 VEH 7 Right 1975 
2 HSP 7 Left 1640 
4 HSP 7 Left 1004 
6 HSP 7 Left 1025 
11 HSP 7 Left 1016 
2 HSP 7 Right 2112 
4 HSP 7 Right 2033 
6 HSP 7 Right 2566 
1 VEH 14 Left 1996 
2 VEH 14 Left 1429 
3 VEH 14 Left 1851 
4 VEH 14 Left 1774 
1 VEH 14 Right 2322 
2 VEH 14 Right 2059 
3 VEH 14 Right 2333 
4 VEH 14 Right 2382 
1 HSP 14 Left 1890 
2 HSP 14 Left 1389 
3 HSP 14 Left 1619 
4 HSP 14 Left 1591 
1 HSP 14 Right 2392 
2 HSP 14 Right 2224 
3 HSP 14 Right 2284 
4 HSP 14 Right 1662 
1 VEH 21 Left 2170 
2 VEH 21 Left 2472 
3 VEH 21 Left 2159 
1 VEH 21 Right 2759 
3 VEH 21 Right 1869 
4 VEH 21 Right 2386 
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3 HSP 21 Left 1824 
4 HSP 21 Left 2128 
5 HSP 21 Left 2143 
3 HSP 21 Right 1949 
4 HSP 21 Right 2619 
5 HSP 21 Right 2296 
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Protein Assay Data 
 
Subject ID Group Day TA ug/mg of Muscle Wet Weight 
1 VEH 1 Left 60.64 
2 VEH 1 Left 45.78 
3 VEH 1 Left 33.18 
4 VEH 1 Left 36.47 
5 VEH 1 Left 34.96 
6 VEH 1 Left 33.28 
7 VEH 1 Left 38.58 
1 VEH 1 Right 64.29 
2 VEH 1 Right 61.01 
3 VEH 1 Right 57.33 
4 VEH 1 Right 70.59 
1 HSP 1 Left 67.24 
2 HSP 1 Left 44.41 
3 HSP 1 Left 32.17 
4 HSP 1 Left 36.36 
5 HSP 1 Left 40.37 
6 HSP 1 Left 45.65 
1 HSP 1 Right 69.50 
2 HSP 1 Right 59.72 
3 HSP 1 Right 54.30 
4 HSP 1 Right 66.14 
1 VEH 3 Left 66.27 
2 VEH 3 Left 50.21 
3 VEH 3 Left 53.30 
4 VEH 3 Left 43.43 
5 VEH 3 Left 45.99 
6 VEH 3 Left 48.55 
1 VEH 3 Right 69.54 
2 VEH 3 Right 59.84 
3 VEH 3 Right 65.31 
4 VEH 3 Right 70.62 
1 HSP 3 Left 63.33 
2 HSP 3 Left 52.23 
3 HSP 3 Left 55.25 
4 HSP 3 Left 47.83 
5 HSP 3 Left 52.48 
6 HSP 3 Left 49.97 
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1 HSP 3 Right 67.07 
2 HSP 3 Right 83.60 
3 HSP 3 Right 62.81 
4 HSP 3 Right 62.44 
1 VEH 7 Left 62.22 
2 VEH 7 Left 62.99 
3 VEH 7 Left 71.22 
4 VEH 7 Left 56.47 
5 VEH 7 Left 61.99 
1 VEH 7 Right 60.39 
2 VEH 7 Right 63.63 
3 VEH 7 Right 68.65 
4 VEH 7 Right 69.60 
1 HSP 7 Left 61.69 
2 HSP 7 Left 64.83 
3 HSP 7 Left 63.41 
4 HSP 7 Left 62.12 
5 HSP 7 Left 63.73 
6 HSP 7 Left 60.59 
1 HSP 7 Right 74.57 
2 HSP 7 Right 62.72 
3 HSP 7 Right 56.46 
4 HSP 7 Right 65.12 
5 HSP 7 Right 63.06 
1 VEH 14 Left 65.72 
2 VEH 14 Left 60.77 
3 VEH 14 Left 71.26 
4 VEH 14 Left 50.73 
5 VEH 14 Left 63.49 
6 VEH 14 Left 63.96 
1 VEH 14 Right 74.33 
2 VEH 14 Right 61.19 
3 VEH 14 Right 63.88 
4 VEH 14 Right 66.22 
5 VEH 14 Right 70.52 
1 HSP 14 Left 50.60 
2 HSP 14 Left 60.79 
3 HSP 14 Left 63.09 
4 HSP 14 Left 61.04 
5 HSP 14 Left 57.26 
1 HSP 14 Right 64.22 
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2 HSP 14 Right 60.60 
3 HSP 14 Right 62.62 
4 HSP 14 Right 65.22 
1 VEH 21 Left 63.29 
2 VEH 21 Left 61.43 
3 VEH 21 Left 55.23 
4 VEH 21 Left 64.36 
5 VEH 21 Left 63.68 
1 VEH 21 Right 62.76 
2 VEH 21 Right 62.00 
3 VEH 21 Right 59.83 
4 VEH 21 Right 64.17 
5 VEH 21 Right 69.86 
1 HSP 21 Left 55.12 
2 HSP 21 Left 55.94 
3 HSP 21 Left 67.86 
4 HSP 21 Left 56.47 
5 HSP 21 Left 60.46 
6 HSP 21 Left 62.14 
1 HSP 21 Right 50.81 
2 HSP 21 Right 61.57 
3 HSP 21 Right 52.81 
4 HSP 21 Right 61.08 
5 HSP 21 Right 63.97 
6 HSP 21 Right 63.60 
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Western Blot Data 
 
Subject ID Group Day TA Hsp70 GAPDH TNF-alpha Myogenin 
3 VEH 1 Left 0.11 0.04 
  
8 VEH 1 Left 0.55 0.02 0.51 0.73 
5 VEH 1 Left 0.23 0.05 0.59 0.40 
9 VEH 1 Left 0.09 0.01 0.81 0.63 
4 VEH 1 Left 
  
0.87 0.54 
7 VEH 1 Left 0.17 0.38 1.20 1.28 
10 VEH 1 Left 0.23 0.06 1.37 1.05 
3 VEH 1 Right 0.37 3.20 
  
5 VEH 1 Right 0.16 5.17 0.09 0.14 
4 VEH 1 Right 0.51 3.16 0.10 0.17 
8 VEH 1 Right 0.36 3.92 0.11 0.16 
3 HSP 1 Left 0.23 0.07 
  
8 HSP 1 Left 0.31 0.41 0.48 0.40 
4 HSP 1 Left 0.53 0.29 0.61 0.72 
10 HSP 1 Left 0.13 0.08 1.15 0.82 
5 HSP 1 Left 0.17 0.01 1.24 0.60 
7 HSP 1 Left 0.06 0.19 1.58 0.78 
3 HSP 1 Right 1.82 4.10 
  
5 HSP 1 Right 1.48 3.53 0.06 0.14 
4 HSP 1 Right 2.39 1.95 0.06 0.12 
8 HSP 1 Right 1.98 2.09 0.11 0.12 
3 VEH 3 Left 0.49 0.06 
  
10 VEH 3 Left 0.63 1.08 0.26 0.36 
7 VEH 3 Left 0.32 0.77 0.34 0.44 
8 VEH 3 Left 0.51 0.35 0.49 0.83 
9 VEH 3 Left 0.12 0.05 0.52 0.32 
4 VEH 3 Left 0.54 1.10 0.71 0.94 
3 VEH 3 Right 0.44 3.40 
  
10 VEH 3 Right 0.72 3.86 0.03 0.06 
8 VEH 3 Right 0.38 3.09 0.10 0.13 
4 VEH 3 Right 0.57 4.16 0.10 0.04 
3 HSP 3 Left 0.39 0.11 
  
4 HSP 3 Left 0.25 0.23 0.36 0.44 
7 HSP 3 Left 0.36 1.51 0.48 0.46 
8 HSP 3 Left 0.68 0.75 0.75 0.88 
5 HSP 3 Left 0.27 0.76 0.89 0.41 
10 HSP 3 Left 0.15 0.08 1.09 0.64 
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3 HSP 3 Right 2.01 2.90 
  
4 HSP 3 Right 2.04 2.61 0.06 0.06 
5 HSP 3 Right 1.61 2.67 0.13 0.06 
8 HSP 3 Right 1.76 2.50 0.15 0.06 
9 VEH 7 Left 0.45 2.25 0.08 0.20 
4 VEH 7 Left 0.84 3.45 0.11 0.18 
1 VEH 7 Left 1.05 3.19 0.13 0.20 
10 VEH 7 Left 1.77 1.90 0.15 0.07 
5 VEH 7 Left 0.73 1.92 0.31 0.25 
4 VEH 7 Right 0.31 3.28 0.04 0.12 
10 VEH 7 Right 1.10 2.63 0.04 0.05 
5 VEH 7 Right 0.22 1.52 0.07 0.02 
1 VEH 7 Right 0.53 2.71 0.16 0.16 
5 HSP 7 Left 2.89 2.94 0.05 0.32 
9 HSP 7 Left 2.00 1.49 0.36 0.76 
7 HSP 7 Left 0.78 1.54 0.38 0.46 
8 HSP 7 Left 1.72 3.24 0.42 0.60 
10 HSP 7 Left 2.27 2.08 0.54 0.50 
10 HSP 7 Right 2.68 2.55 0.04 0.08 
9 HSP 7 Right 3.00 2.78 0.10 0.15 
5 HSP 7 Right 2.48 3.77 0.13 0.15 
8 HSP 7 Right 2.47 3.45 0.18 0.18 
6 VEH 14 Left 1.23 3.06 0.04 0.23 
10 VEH 14 Left 1.02 2.99 0.04 0.15 
9 VEH 14 Left 0.32 2.14 0.05 0.10 
5 VEH 14 Left 0.84 2.66 0.17 0.17 
8 VEH 14 Left 0.84 3.49 0.21 0.22 
10 VEH 14 Right 0.31 3.53 0.05 0.05 
6 VEH 14 Right 0.26 2.87 0.06 0.07 
5 VEH 14 Right 0.34 3.10 0.07 0.12 
8 VEH 14 Right 0.36 2.02 0.07 0.07 
6 HSP 14 Left 2.75 3.07 0.04 0.34 
8 HSP 14 Left 3.61 3.29 0.10 0.18 
5 HSP 14 Left 3.21 3.92 0.12 0.13 
10 HSP 14 Left 3.37 3.24 0.16 0.18 
7 HSP 14 Left 3.00 2.28 0.20 0.33 
6 HSP 14 Right 2.76 3.12 0.05 0.05 
5 HSP 14 Right 2.36 3.06 0.06 0.18 
10 HSP 14 Right 3.53 3.15 0.08 0.17 
8 HSP 14 Right 3.69 2.47 0.08 0.04 
2 VEH 21 Left 0.54 3.02 0.04 0.06 
 113 
 
3 VEH 21 Left 0.17 2.57 0.18 0.15 
4 VEH 21 Left 0.82 3.05 0.25 0.28 
5 VEH 21 Left 0.33 1.83 0.56 0.31 
2 VEH 21 Right 0.27 2.10 0.06 0.16 
1 VEH 21 Right 0.04 4.32 0.14 0.11 
5 VEH 21 Right 0.12 2.47 0.28 0.18 
2 HSP 21 Left 3.92 2.22 0.16 0.45 
3 HSP 21 Left 2.50 2.71 0.20 0.31 
5 HSP 21 Left 1.89 3.38 0.25 0.14 
6 HSP 21 Left 1.76 3.69 0.25 0.25 
1 HSP 21 Right 2.09 4.58 0.09 0.08 
2 HSP 21 Right 2.48 2.53 0.12 0.19 
5 HSP 21 Right 2.17 3.14 0.22 0.13 
 
 
